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Abstract 
Background: With the emergence of drug resistance in south East Asia to the very 
efficacious Artemisinin combination Therapies (ACTs) in the treatment of patients with 
malaria, there is need to understand the relationship between human factors, parasite  
diversities, environment and delay to parasite clearance in Cameroon. This can inform 
the control programs against malaria on how to fight ACTs drug resistance. 
 
Objective: This research seeks to assess efficacy and safety of three ACTs and to 
Model the impact of human factors, drugs, and endemicity to response to therapy and 
Malaria parasite clearance time. 
 
Methods: The data for this research is from a study –” Artemisinin-Based Antimalarial 
Combinations and Clinical Response in Cameroon”. This study is a non-inferiority study 
with a 3 arm, open randomised comparative controlled trial. The Target population is 
children under 120months of age with acute uncomplicated P. falciparium malaria. 
Patients were followed up for 42 days and the principal outcome measure is Adequate 
Clinical and Parasitological Response(ACPR) at Day 42. Safety profiles of drugs is 
assessed by Prevalence of adverse events and serious adverse events.  We fit the data 
to two models -A logistic model to understand the response to therapy and a discrete 
time survival model to explore delayance to parasite clearance. The three drugs we 
studied are artesunate amodiaquine, dihydroartemisinin piperaquine and artemeter 
lumefantrine. 
 
Conclusion: Artesunate amodiaquine and dihydroartemisinin peperaquine are safe and 
are atleast not worse off than artemeter lumefantrine in the treatment of Plasmodium 
falciparium malaria in Cameroonian children. No patient individual characteristics 
influence therapy outcome. However the ecological region(site) is important determinant 
in therapy outcome at 0.1 significance level. The levels of alanine aminotransferase, 
haemoglobin, creatinine and interaction between ecological region  and age group of 
children are the main driving force in parasite clearance delay. 
Keywords: non-inferiority, drug resistance, parasite, clearance, endemicity, 
randomised, safety 
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1.1 Background  
Malaria is one of the most devastating parasitic diseases of humans that, continues to 
thrive throughout the world and especially in Sub-Saharan Africa, despite the numerous 
control efforts realized so far. Malaria is caused by blood infection of protozoan 
parasites of the genus Plasmodium, which is transmitted from one human to another by 
female Anopheles mosquitoes. Five Plasmodium species routinely infect humans: 
Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, 
and Plasmodium knowlesi [1]. The high burden of malaria in Africa is due to P. 
falciparum, which adapts and co-spescialises with Anopheles gambiae [2][3] the most 
effective and widespread vector, making it very difficult to control. Presently there are 
about 450 known anopheles species, of which 60 can potentially transmit malaria, with 
regard to their vectorial capacity[2].  
There was an estimated 247 million malaria cases among 3.3 billion people at risk in 
2006, causing nearly a million deaths, mostly of children under 5 years. 109 countries 
were endemic for malaria in 2008, 45 within the WHO African region[4]  . Annually 25 
million pregnancies are potentially at risk [5] with related adverse effects like intrauterine 
growth retardation (IUGR), low-birth weight (LBW) from prematurity, foetal parasite 
exposure and congenital infection, infant mortality (IM) linked to preterm-LBW and 
IUGR-LBW [6]. It is estimated that 75000 to 200000 infants‟ deaths are associated with 
malaria in pregnancy [6]. It has been estimated that the economic burden of malaria is 
extremely high, accounting for a reduction of 1.3% in the annual economic growth rate 
of countries in which malaria is endemic, and that the consequent long-term impact is a 
reduction of gross national product (GNP) to more than half [7]. To reduce the extreme 
burden caused by this disease in Africa, the Millennium Development Goal (MDG) were 
set out with the aim to reduce malaria by 75% by 2015 from its 2005 baseline level with 
an average comprehensive malaria control cost of US$ 3.0 billion per year, or around 
US$ 4.02 billion per African at risk [8] .  
There are three dominant difficulties in maintaining malaria control[9]: (i) parasite 
resistance to safe and affordable antimalarials and the spread of unofficial vendors 
where most of the population go to with elevated risks related to auto-medication 
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(resistance, side-effects etc) (ii) the almost complete demise of vector control programs 
in developing tropical and subtropical countries, and (iii) the failure to develop a 
practical vaccine that prevents malaria. Indeed, genetic diversity due to sequence 
variations in merozoites (1/2) and circumsporozoites (csp) proteins etc, which is the 
proper of malaria parasites and especially P. falciparum has greatly hampered the 
production of a vaccine till date. Nevertheless it is essential in clinical trials so as to 
monitor the spread of resistance especially to artemisinin based combination therapies.  
Since its policy change between 2004 and 2006 for malaria treatment (adoption of first 
and second line treatments for artemisinin-based combination therapies), Cameroon 
national malaria control programs has undertaken to disseminate this shift in all regions 
to inform health workers at public mission and private health facilities. However, much 
still need to be done as there are still gaps in malaria case management in Cameroon 
[10], as compared to other regions of Africa. Deficiencies in the practices of both public 
and private providers compromise the effectiveness and cost-effectiveness of malaria 
case-management. In 2004, malaria was a major public health problem in Cameroon, 
and it was considered the first cause of morbidity. [11]However, the morbidity and 
mortality rates now stand at about 35.88% and 24% respectively.[11] This drop may be 
attributed to the use of Artemisinin-based Combination Therapies (ACTs), Intermittent 
Preventive Treatment (IPT) in pregnant women, and vector control strategies such as 
the use of Long Lasting Insecticide Treated Nets (LLITN) and Indoor residual Sprays 
(IRS) [12].  
The discovery in thai-cambodia that ACTs can suffer from resistance is alerting the 
research community especially in Africa.[13] Molecular Systematic and phylogenetic 
approaches are now standing among others as predictors of resistance spread. It is 
generally hypothesized in terms of homology (similarity attributed to descent from a 
common ancestor) that genes with similar sequences will display similar types of 
functions or regulations. This will help to contain the spread of resistance, which can be 
brought about by population movements and vectors transmission [14], to ACTs but 
also ring alarm for future drug development. 
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Researchers are now focusing on parasite clearance time after administration of ACTs 
and some have reported on the fast clearance (short half life) of artemisinins derivatives 
in Mali [15]. Reports have shown  that drug resistant strains can also rapidly be cleared 
by the system. However delay of parasite clearance time has however been noted with 
artesunate-mefloquine in southern Cambodia[16] [17].  
One of the genes involved in the pharmacogenetics of antimalarials is the NAT2 gene 
(N-Acetyl transferase 2), which encodes the enzyme N-Acetyl transferase 2, involved in 
phase 2 of the biotransformation of antimalarial drugs. [18] The cytochrome CYP gene 
has also been implicated. Many researchers are picking up interest on the inter play of 
nutrition with disease burden. Indeed, results of dozens of epidemiological studies in 
recent years strongly suggest that some minerals (zinc), vitamins (vitamin A) and other 
trace elements in the diet, may reduce the incidence of various degenerative diseases 
(cardiovascular diseases, malaria, cancer, cataracts, macular degeneration) [19]. In the 
other hand It has been suggested that the presence of some elements not yet well 
characterized, in milk favors resistance to malaria in Fulani population compared to non-
Fulani [20]. The Fulani therefore clear parasite faster that the non-Fulani. In two ethnic 
groups, Fulani and Mossi, it was also found that Fulani had lower risks of contracting 
malaria infections [21].This is ascribed to the absence of a C allele in the rs2706384 
gene of interferon regulator factor 1. However, Fulani homozygous individuals to C 
allele has more chances of contracting malaria. It was demonstrated that some genetic 
factors in drug metabolism appeared to be substantial contributors to the observed 
lower efficacy of CoArtem obtained in Cambodia as compared to Tanzania, two different 
ethnic groups. [22]  
There are other contributing factors to the decline of parasite clearance time. In  
Cameroon where ACTs like AL have been massively deployed and are free of charge, 
for pregnant women and children modeling or evaluating these responses is crucial as 
many patients for instance do not always stick to the treatment. This might have 
implication for alternative therapies; the redesign of drug policy.          
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1.1.1 Models on drug resistance and efficacy 
A few models have been fitted using data from different studies to describe patterns in 
anti-malarial drug resistance and efficacy. Some of these models have described 
patterns in drug utilisations, strategies to delay the progress of drug resistance, the role 
of anti-malarials in elimination malaria, and the impact of artemisinin combination 
therapy and long acting treatment in reducing malaria transmission [23], [24], [25], [26].  
The impact on the choice artemisinin combination therapy  and the implementation has 
been described with data from the Thai borders that have shown high drug resistance 
and also have areas of different endemicity [26]. This model has shown that anti-
malarial drug resistance spreads faster in low transmission than in high transmission 
settings. This model has also shown that in low transmission settings, it is treatment 
failure that is the main cause of drug resistance. Artemisinin has been shown to delay 
the spread when coverage rates are high and that an exponential inverse effect would 
be seen in terms of spread of drug resistance if coverage is not adequate. The model 
predicts that the proportion of human population with residual drug levels to be the main 
determining factor of drug resistance in a setting of high transmission. This model 
measures rather the spread of drug resistance with the assumption that it already exist. 
Hybrid modeling, of three potential benefits of multiple first line treatments (MFTs) have 
been used to quantify the effectiveness of multiple deployment of artemisinin 
combination therapies [24]. These models describe the effects reducing the chances of 
a parasite spreading to other hosts, reducing drug pressure and also reducing parasite 
fitness to emergence of drug resistance. These models point to the fact that the global 
emergence of resistance to artemisinin combination therapies is approximately 10 years 
and that multiple first line therapies in has the potential of ensuring a long term efficacy 
of artemisinin combination therapies, starting with the partner drug. 
Other models using malaria data have been used to predict the impact of malaria 
transmission with the roll out of artemisinin combination therapies and alternative first 
line treatments in different levels of malaria transmission [23]. This describes malaria 
transmission in humans and also mosquito populations with respect to some variables 
that are likely to have an impact on malaria transmission. This model predicts that 
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reduction in the prevalence and incidence of infection associated with a complete switch 
to artemisinin combination therapies would have more impact in areas where there is a 
low initial transmission that those with a high transmission rate. This model also shows 
the advantage of long acting treatments over some currently used artemisinin 
combination therapies in areas of high transmission. This model recommends that in 
order to make a policy change on an anti-malarial drug, for any community, there is a 
need to assess the level of malaria transmission in the community and the half life of the 
drug under consideration. There are other researchers that have looked at the 
epidemiological models for the spread of drug resistance and others on the evolution of 
multi drug resistance [27][28]. The epidemiological models which basically use the 
Macdonald-Ross[29] model of malaria transmission, have shown that malaria drug 
resistance does not spread except a fraction of people that are infected but not treated 
does not go below a thresh hold point. The evolution of multi resistance model explores 
resistance using the parasite population structure. The premise of the multi drug 
resistance models is that the frequency of mutation change rate in the parasite 
population depends on the proportion of host treated with drugs and the parasite 
transmission rate. This model has shown that reducing transmission rate is effective in 
reducing the spread of drug resistance. 
1. 2 Rationale of the study 
Anti-malarial drug studies conducted between 1986 and 1992 when monotherapies 
were still the drugs for treatment of malaria in Cameroon have reported different levels 
of resistance in different regions. These different levels of resistance, according to the 
studies depended on what anti-malarial drug was being considered.  For example 
chloroquine resistance was shown to vary between 40-86% in the south and 20-25% in 
the north. Mefloquine resistance was rather found to be higher in the north (25%) than 
in the south (2%) . There have been also studies that have shown antifolate failures of 
12% and 43% in vivo and in vitro respectively in Yaoundé with resistance to 
aminoquinolines remaining high in the years between 1994 and 2002. Even though in 
yaounde, the capital city of Cameroon, amodiaquine and pyronaridine were shown to be 
efficacious in this same period [30], [31] there were reports in the later years 2005-2010 
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of declining rates of amodiaquine efficacy or in combination with sulphadoxine 
pyrimethamine [32], [33] 
The replacement of monotherapies by artemisinin combination therapies in the 
treatment of malaria has greatly improved treatment outcome.[34] Artesunate-
amodiaquine and artemether-lumefantrine, are first line and second line treatments of 
Plasmodium falciparum Malaria in Cameroon  respectively .  These choices for first and 
second line treatment were made without prior data on the efficacy of these drugs. In 
Cameroon one of the limitations of new treatment regimens is the frequent stock outs, 
treatment cost and rational use. In the urban areas there are competing artemisinin 
combination therapies offered by the private sector and sometime roadside medication 
vendors[19] Dihydroartemisinin-piperaquine (Aterkin®) has been introduced 
commercially and is sold in the drug stores.  This led to the set objectives to evaluate 
the efficacy and safety of the ACTs-artesunate-amodiaquine dihydroartemisinin-
piperaquine and artemether-lumefantrine as the comparator.   
The emergence of drug resistance to the very efficacious artemisinin combination 
therapies around south east Asia [34] remains a great concern to malaria control. There 
are yet no methods to tracking this resistance. Even though there are artemisinin 
resistance containment strategies spearheaded by WHO, combating this resistance will 
require many unknowns to be addressed first [10]. Therefore, modeling the artemisinin 
combination therapies response to human, ecological and parasite factors has a 
potential to unravel what might be playing a role in the artemisinin resistance. The time 
to parasite clearance with respect to these factors could also be helpful in 
understanding the progress of artemisinin resistance. 
1.3 Objective of study 
       1.3.1 Primary Objectives 
To assess the efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine, 
in comparison with artemether-lumefantrine during 42 days follow up period in 
children with acute uncomplicated P. falciparum malaria, in two different endemic 
areas.  
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    1.3.2 Secondary Objectives  
(i) To assess the efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine, 
in comparison with artemether-lumefantrine during 14 and 28 days follow up period 
in children with acute uncomplicated P. falciparum malaria in two different endemic 
areas.   
(ii) To evaluate the safety of artesunate-amodiaquine, dihydroartemisinin-piperaquine 
,in comparison with artemether-lumefantrine  during  42 days follow up period in 
children with acute uncomplicated P. falciparum malaria. 
(iii) To determine parasite clearance time (PCT) and fever clearance time (FCT) 
following administration of the three trial regimens. DHAP. ASAQ, AL 
(iv) To investigate the treatment response based on WHO criteria (WHO, 2003)  in 
patients in all groups after treatment. 
(v) To investigate the Single Nucleotide Polymorphisms (SNPs) in gene markers 
associated with drug resistance 
(vi) To establish the Safety profile and association with metaboliser status  
1.3.3 Modelling response to therapy and parasite clearance time 
(i) Model the effects of drug use, over prescription, auto medication and presence of 
multiple drugs, ethnicity and endemic region, baseline vital signs, genetic diversity of 
parasite strains, safety profiles to response to therapy 
(ii)Model the delay in parasite clearance time with respect to drug use, auto 
medication, ecological region and ethnicity, diversity of parasite strains, safety 
profiles. 
1.4 Significance of Study 
Results from this study would help inform policy on the choices of first line treatment 
against malaria. It would also provide information on the segmentation of Cameroon to 
identify better ecological and human responses to treatment. This study has the 
potential of providing information to  track drug resistance for better policy to understand 
when to withdraw or advice for a change of policy.  
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2.1 History of Malaria  
2.1.1 From mono-therapy to combination therapy 
The name malaria comes from the Italian word Mal aria that means bad air.  It is also 
called “paludism” from the Latin word “paludis” which means marshes. These two 
names reflect the early views that the disease is spread by unhealthy mist from 
marshes. Although people were unaware of the origin of malaria and the mode of 
transmission, protective measures against the mosquito have been used for many 
centuries. Inhabitants of swampy regions of Egypt were recorded as sleeping in tower-
like structures out of the reach of mosquitoes, whereas others slept under nets as early 
as 450 B.C. [35] 
Ancient treatments were available like infusions of qinghao (Artemesia annua) used by 
Chinese in the last 200 years. Don Francis in 1630 taught native Indians in Peru the 
excellence of the fever tree to fight malaria.  In 1638, the physician of the wife of the 
Spanish viceroy in Peru (the countess of Chincton) treated her for malaria using the 
bark of a tree, which prevented shivering. This worked to cure her from the malaria even 
though he did it for the wrong reason.  Linnaeus later named the tree after her. Around 
the same time the cinchona bark was introduced into Europe and called “Jesuit 
Powder”. Protestants were suspicious of anything linked to the Jesuits, and refused 
taking it and dubbed it, “the powder of the devil”.  In the 1670s, an Englishman, Robert 
Talbor used the bark of this same tree to treat Charles II for which he was made a 
knight.  He was later made Chevalier for using the same bark to treat the son of the 
French King, the Dauphin. [36] 
In 1830, Pelletier and Caventou isolated quinine and cinchinine, two alkaloids active 
against the malaria parasite from this tree.  In 1836 Charles Ledger while collecting 
plants in Peru decided to find the source of the cinchona bark.  He came across a 
species with a high concentration of the active ingredient, quinine, and it was named 
after him.  While the Dutch welcomed it and started plantations in Java, the British 
turned it down.  The bark of this tree was later added to wine in which it metamorphosed 
into gin and became a delicacy for British colonialists.  
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In 1889, Laveran, traced the pathogenic agent of malaria for which he was awarded the 
Nobel Prize for medicine in 1907. This was later elucidated by the classification of three 
Plasmodium species, falciparum, vivax and malariae by Golgi and collaborators. Ross 
only suspected the involvement of the female mosquito in 1897.  Grass later confirmed 
this assertion in 1898.   Stephens classified the fourth plasmodium species, ovale, in 
1922. The discovery of quinine had profound influence on world history because 
European soldiers survived in Africa as well as the allied forces in the Pacific during 
World War II. The tropics now became more habitable by colonialists leading to a rapid 
colonial expansion in Africa.  In the United States, it made Westward expansion in the 
1830s possible because settlers were given quinine.  The capture of the Javanese 
Cinchona plantations caused the Americans to start a huge project to find new 
antimalarial drugs.  This led to the discovery of an 8-amino - quinoline, called atebrine.  
Unfortunately, this had only marginal activity against human malaria but with very 
serious side effects up to temporary insanity.  In 1934, the Germans discovered a 4-
aminoquinoline compound, which was very active against malaria, and called it 
Sontochin.  In 1943, the French in North Africa informed the Americans of Sontochin.  
The Americans modified it slightly and renamed it “Chloroquine”.  This became the drug 
of choice for treatment of human malaria.  This cheap and available drug however had 
its hopes dampened when resistance was proven in 1964. This resistance has 
continued to spread in endemic zones and is also spreading to other antimalarial drugs 
that have been discovered later on.[36] 
Important attributes for the successful implementation of antimalarial drugs are good 
tolerability and safety (especially in young children), affordability, availability in endemic 
countries and short course regimens [37]. Drugs that have been used against malaria 
as monotherapies span from quinine, chloroquine, amodiaquine, mefloquine, 
piperaquine, lumefantrine, primaquine, atovaquone, to antifolate drugs (sulfadoxine, 
pyremithamine, proguanil etc). Almost all antimalarials are now to be administered as 
part of a combination therapy, with each targeting distinct mechanism within the 
parasite. The main goal is to achieve maximal suppression of parasites and delaying 
the onset of resistance that has been ascribed to these drugs. Current artemisinin-
based combination therapies include artemether–lumefantrine (Coartem, presently the 
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most commonly used ACT worldwide), artesunate–mefloquine, artesunate–
amodiaquine, artesunate–sulfadoxine–pyrimethamine, dihydroartemisinin–piperaquine, 
and artesunate–pyronaridine [38].  
Cameroon, like many other African countries, following the increasing resistance of 
chloroquine[32]had adopted Amodiaquine and Sulphadoxine-pyremithamine as first- 
and second- line drugs in 2002 and 2004, respectively. Unfortunately the cure rate of 
these two drugs was proven to deteriorate as monotherapies in five study sites of 
Cameroon [32]. In this view there was an increasing need to shift this time to the 
adoption of combination therapies in 2004 with Artesunate-AmodiAQuine (AS-AQ, Co-
Arsucam™) as 1st line drug treatment and in 2006 with Arthemeter-Lumefantrine (AM-
LM or AL, Coartem®) as alternative therapy. 
Combination therapies are used as single-first line therapies. It has been found that 
using these combination therapies as multiple-first line therapies (MFTs) will have 
beneficial effects on the clinical outcome of malaria patients. ACTs can be shared 
among different population groups, in terms of age for instance (young and adults), at 
home-based or clinic. Many authors advocate a switch in favor of these MFTs in the 
malaria treatment policy of countries given the uncertainty behind the emergence of 
resistance to ACTs. MFTs have the advantage of delaying emergence to 
resistance/treatment failure and if resistance it reduces the spread [39][24]. This 
advocacy seems to be governed by research on modelling simulating the use of ACTs 
as MFTs and their benefits. 
 
2.1.2. First report on Artemisinin combination therapy resistance 
Antimalarial combination therapy is defined as the simultaneous use of two or more anti 
malarial drugs, which may either be co-formulated or co-administered, with different   
biochemical targets in the parasite or host tissue, whose combined effects are either 
additive or synergistic . 
According to WHO, the objectives of an antimalarial treatment policy are to: ensure 
rapid cure of the infection; reduce morbidity and mortality, including malaria-related 
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anaemia; prevent the progression of uncomplicated malaria into severe and potentially 
fatal disease; reduce the impact of malaria infection on the foetus during pregnancy; 
reduce the reservoir of infection; prevent the emergence and spread of drug resistance; 
and prevent malaria in travelers [40]. The combination therapy exploits the difference in 
time of action of each partner drug due to their different half-lives. In addition, the use of 
drugs in combination shortens duration of treatment, hence increasing compliance, and 
decreasing the risk of resistant parasites arising through mutation during therapy[41].  
In the last decade artemisinin combination therapy has become a key component of 
malaria control and elimination efforts. It was of great concern therefore when reports of 
declining efficacy of artesunate-Mefloquine began to surface from the western and 
Southern region of Cambodia [42][17], and from the Thai-Myanmar border [13]. It was 
however difficult to ascertain whether the decline is due to artesunate or mefloquine 
[43].  
Data from Africa indicate that the use of ACTs lead to the selection of parasites 
resistant to the long-acting partner drugs[44].Mutations in pfatp6 (P. falciparum Ca2+ 
transporting ATPase 6) have been associated with decreased artemether susceptibili ty 
in field isolates from French Guyana [45].In this view it is important to monitor the 
spread of resistance as many molecular phylogenetic analyses have been able to do 
with drugs like sulfadoxine. 
Currently, neither genotypic nor in vitro assays can reliably distinguish parasite 
populations that will respond slowly to the artemisinins. Nevertheless, novel approaches 
for assessing in vitro drug susceptibility are underway in several laboratories focused on 
drug responses, and changes in transcription and metabolic patterns [46][47][48]. 
2.2 Epidemiology of Malaria 
2.2.1 Human malaria parasites and geographical distribution   
Plasmodium species are generally distributed worldwide, but each species varies in 
distribution in relation to factors such as climatic conditions, blood group types, etc 
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Plasmodium falciparum: this is the most virulent species with greatest impact on 
human health in terms of mortality and morbidity. It is associated with the subtertian 
malignant periodic fevers occurring every 48 hours and the severe and complicated 
malaria. It parasitizes all red blood cells (RBCs), and this contributes to the higher 
parasitemia most often observed in infected patients. P.falciparum is a pan-tropical 
distributed parasite mostly prevalent in Africa and some parts of Asia.  
Plasmodium vivax: accounts for the relapse cases of malaria, by forming hypnozoites, 
the dormant form of parasite. Unlike P. falciparum, the latter is mostly associated with 
high morbidity [49] and benign tertian periodic fevers occurring every three days. P. 
vivax prefers young erythrocytes. It is a pan-tropical and temperate distributed parasite, 
mostly in Asia South and Central America. The absence of Plasmodium vivax in black 
population of West and Central Africa is due to the absence of the Duffy antigen on their 
red blood cells [50]. These populations are homozygous to the gene responsible for the 
expression of the Duffy antigen.  
Plasmodium malariae: the distribution of P. malariae generally coincides with that of P. 
falciparum in areas of endemicity in Africa; they form a mixed infection [51].This parasite 
causes the quartan malaria with fevers occurring every four days and prefers old 
erythrocytes, one of the reasons why its parasitaemia is much fewer than that of P. 
falciparum and P. vivax. P. malariae is a tropical species mainly distributed in sub-
Saharan Africa, most of south East Asia, Indonesia, many islands of the western pacific.  
Plasmodium ovale: Like P. vivax this parasite also causes the relapse cases of 
malaria and its tertian benign form. This parasite has the tendency to develop in 
younger erythrocytes and its Giemsa differentiation from vivax is most difficult. 
However, unlike P. vivax it does not modify RBCs as much and produces much fewer 
merozoites [52]. It is highly distributed in sub-Saharan Africa, New Guinea and 
Philippines. Lysenko et al in 1969 reported for the natural occurrence of this species in 
sub-Saharan Africa and the islands of the western pacific.  
Plasmodium knowlesi: It naturally infects macaques and it is mainly found in 
Southeast Asia. This species was first identified in a long tailed macaque, Macaca 
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fascicularis. It is now known as a zoonotic species because it can also infect humans 
[1]. P. knowlesi has a 24 hours erythrocytic cycle and the disease progression can be 
fast [53].  
2.2.2 Life cycle and mode of transmission 
 Mode of transmission 
The malaria parasite can be transmitted through several ways which include; transfer of 
parasitized red cells from an infected mother to the child transplacentally or during labor 
in which case it is known as congenital malaria [54] during transfusion of blood from 
infected donors, or through needle-stick injuries [55] often accidentally among health 
care professionals or due to needle sharing among drug addicts. In addition to these, 
the malaria parasite is principally transmitted by the bite of an infected female 
Anopheles mosquito. Sporozoites contained in the saliva of the mosquito (vector) are 
inoculated into the blood of a human host when the mosquito takes a blood meal. Once 
in the human host, the parasite continues part of its life cycle which had started in the 
mosquito host. 
 
 
Figure 2.1:  Life Cycle of the malaria parasite 
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Plasmodium life cycle encompasses two main stages that govern the infectious process 
required for parasite‟s development within the definitive and intermediate host. The 
asexual stages constitute two cycles, the exo-erythrocytic schizogony cycle (the liver 
stage) and the erythrocytic schizogony cycle. The sexual phase splits between humans 
and mosquitoes. In humans, there is formation of male and female gametocytes that 
end in mosquito develops into gametes, mating and differentiation of the resulting 
zygote into multiple forms within the life cycle of these parasites, the key points for 
microscopic diagnosis are the gametocyte, the ring stage, the mature trophozoites, and 
the schizont points. 
 Asexual reproduction in the vertebrate host  
This is also known as liver cell schizogony and repeated red cell schizogony cycles and 
the formation of gametocytes.  Infection in the vertebrate host commences when an 
infected mosquito in the course of feeding injects sporozoites into the peripheral 
circulation of the host, which finally results in the invasion of hepatocytes. Nevertheless, 
this is not done directly because new researches on intra-vital imaging have shown that 
the parasite can settle in the skin for almost six weeks [56] and that nearly one third can 
leave the injection site and drain to the lymph nodes through Lymphatic systems [57]. 
Other sporozoites trickle into the blood stream towards the liver where the exo-
erythrocytic schizogony can now take place. 
 The exo-erythrocytic stage of malaria parasites in humans 
Schizogony, refers to a replicative process in which parasite undergoes multiple rounds 
of nuclear division without cytoplasmic division (cytokinesis) followed by a segmentation 
to form progeny. The sporozoites remain in and may invade the Kuppfer cells in the liver 
(or the parasite may be phagocytosed) but the former are not able to develop in those 
cells and so die shortly after invasion. This process of invasion is favored by the motility 
properties of the sporozoites, driven by molecular molecular mechanisms that involve 
two molecules; the circumsporozoite protein (CSP) and thrombospondin-related 
adhesive protein (TRAP) [45] [46]. After their arrest in the liver sinusoids, sporozoites 
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detach themselves from the glycosaminoglycans, traverse the Disse space (lying 
between the sinusoidal cell layer and the hepatocytes) and enter the hepatocytes. 
 
 The liver trophozoite develops into a mature schizont (the multinucleated stage of the 
parasite) and finally a large number of merozoites are released. The mature schizont is 
30-70 μm large, has no pigment (there is no hemoglobin in the hepatocyte), and 
occupies the entire cell cytoplasm. The length of the schizogonic liver cycle is constant 
for each Plasmodium species to the extent that it can be considered a taxonomic 
character. The liver cycle ends when the mature schizont ruptures and releases the 
merozoites into the sinusoids of the liver. Released merozoites can only invade a red 
blood cell.  
Two species of human malaria determine a relapsing infection: P.vivax and P.ovale. In 
these two species some of the liver trophozoites immediately start the exo-erythrocytic 
schizogonic cycle which has been described above, while others remain into the liver in 
a latent (dormant) stage for varying periods of time and are termed hypnozoites. The 
length of the period of dormancy varies with the sub populations of P.vivax and P.ovale.  
A single inoculation of sporozoites of a relapsing species contains a mixture of 
genetically distinct parasites that give rise to discrete subpopulations of exo-erythrocytic 
trophozoites. The number of relapses, and their periodicity, seems to be a characteristic 
of the parasite strain.   
 The erythrocytic stage of malaria parasites in humans 
The blood phase of the life-cycle is initiated when the merozoites from liver schizonts 
are discharged into the circulation [60]. The merozoite is 1 μm in diameter, consisting of 
a single nucleus and adjacent cytoplasm. As earlier mentioned, apicomplexan possess 
the capability of infecting RBCs because of their apical complex made of specialized 
organelles such as rhoptries, densed granules, micronnemes and  apicoplast [61]. With 
these, it invades almost immediately an erythrocyte to enter its trophozoite stage. A 
vacuole is produced by the parasite which assumes the characteristic ring form (the 
young trophozoite). Within 12-24 hours, as the parasite grows, the cytoplasm expands, 
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the vacuole slowly disappears and a characteristic parasitic pigment becomes visible 
within the cytoplasm. At the end of this phase the trophozoite has a single nucleus, a 
large cytoplasm, no vacuole, and a variable amount of pigment. The nucleus starts to 
divide approximately 30 hours after invasion.  As nuclear division produces two or more 
nuclei the parasite enters the stage of a schizont. Nuclear division continues until an 
appropriate number of merozoites are produced: approximately 36 for P.falciparum, 24 
for P.vivax and P.ovale, 12 for P. malariae. At the end of this phase the schizogonic 
cycle is completed, the erythrocyte ruptures releasing the merozoites into the blood 
stream and determining the typical malaria paroxysm. The merozoites discharged into 
the circulation invade new erythrocytes to repeat the schizogonic cycle until the process 
is inhibited by the specific immune response or by chemotherapy. 
The erythrocytic stages of malaria parasites has several important implications in 
clinical practice; first, this is the only stage causing the complex and varying spectrum of 
symptoms characterizing the disease in humans, secondly, the recognition of parasites 
in the blood of a patient allows the diagnosis of the infection and the differentiation of 
the various species of the causing agent. The time required to complete the erythrocytic 
cycle is a fixed characteristic of the parasite species; P. falciparum, and P. vivax, have a 
48-hour development period, in P.ovale it lasts 50 hours, 72 hours P. malariae and 
24hours for P. Knowlesi.  In practice, however, the typical periodicity of malaria 
paroxysm cannot be recognized in the initial periods, since most parasite populations 
are heterogonous and continuous fever therefore results from the completion of 
asynchronized schizogonic cycles.  
 Gametocytogenesis 
In the course of a schizogonic cycle (within a red blood cell) some of the merozoites 
become differentiated into sexual forms (the gametocytes). The first stage of the 
maturation process is the ring form. In P. falciparum, the ring form has variable size, the 
smallest are only 1.2μm in diameter, tend to adhere to the internal surface of the 
erythrocyte and the nucleus is often divided to show two chromatin dots. The ring form 
is the only asexual stage usually identifiable in the periphearal blood of patients with P. 
falciparum infection because more mature stages of this species adhere to the 
19 
 
endothelium of post-capillary venules in the tissue.  P. malariae trophozoites are regular 
in shape (except those assuming a characteristic band form across the erythrocyte), 
with a small vacuole, early and abundant pigment, no stippling. 
 Two types of gametocytes are found in the peripheral blood, the female macro-
gametocytes and the male micro-gametocytes. They can be differentiated by the fact 
that in the male parasite nuclear material is dispersed while in the female parasite it is 
condensed. These gametocytes are necessary for the perpetuation of the population 
however, for this to happen (because they cannot leave the blood stream on their own) 
they need an outside help from the female Anopheles mosquitoes.  
 The sporogonic cycle in the mosquito 
Female mosquitoes seek a blood meal as a protein source for egg production.  For the 
parasites to be transmitted the mosquito needs to bite twice, firstly to become infected, 
and secondly to infect, after completion of sporogonic development [2]. In the mosquito, 
the parasite undergoes gametogenesis, fertilization and sporogony. When the mosquito 
feeds on human, the merozoites drawn from the bloodstream are digested in the 
stomach of the mosquito while the gametocytes develop in the intestine into mature 
cells called gametes, the female ovule and the male spermatozoon (gametogenesis).  
As soon as gametocyte reaches the midgut of the insect the female gametocyte shed 
the red blood cell and remains free in the extracellular space as a macrogamete. The 
male gametocyte nucleus divides into eight sperm-like flagellated microgametes each of 
which also leaves the erythrocyte reaches the midgut and actively moves to fertilize a 
macrogamete. Exflagellation of the microgametocyte is triggered by factors present in 
the mosquito midgut and begins about ten minutes after the blood meal. The result of 
the fertilization process is the zygote, which develops into the elongated, slowly motile 
diploid ookinete within 18 hours from the blood meal. The ookinete actively penetrates 
the peritrophic membrane and the epithelium of the midgut and settles beneath the 
basal lamina of the outer gut wall, where it develops into a non motile oocyst [62]. The 
product of the mature oocyst is the sporozoites, narrow and curved in shape, actively 
motile, 10-15 μm in length. The sporozoites actively leave the cyst passing through 
small perforations without destroying the wall, at least till most of the parasites have 
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been released, and move into the haemocelomic space of the insect. The sporozoites 
migrate and reach the salivary glands where they penetrate the basal membrane, pass 
intracellularly through a secretory cell and settles in the salivary duct with the aid of 
adhesion molecules like TRAP and CSP [59]. When the mosquito feeds, the salivary 
fluid (which has anti-clotting properties) and  its content of sporozoites are actively 
injected into the vertebrate host to start another asexual replicative cycle. 
2.2.3 Transmission and Endemicity 
Endemicity refers to a situation where disease is habitually present within a given 
geographic area. Malaria endemicity can be classified using the transmission intensity, 
the entomological inoculation rate (EIR) and clinical parameters.   
Transmission intensity: According to MacDonald (1957), malaria intensity can be 
categorized into two types, which are stable and unstable malaria.  
Stable malaria refers to a situation where the population is continuously, exposed to a 
constant rate of malaria inoculation. The level of infection is sufficiently high to engender 
a considerable level of clinical immunity (the presence of parasitaemia in the absence of 
malaria related symptoms) within a population. Unstable malaria appears when a 
population is exposed to an irregular transmission rate. In unstable malaria conditions, 
all age groups are at higher risks. The spatial and temporal characteristics of unstable 
malaria are associated with lower level of clinical immunity within a population and the 
propensity for epidemics. Travellers, upon return may suffer from drastic malaria 
disease if not treated. Clinical immunity occurs in the context of premunition often 
termed partial immunity [9]. It is defined as the presence of an immune response that 
produces control of but not complete elimination of parasitaemia. Epidemic malaria, 
which is an extreme form of unstable malaria, can be described as a sharp increase in 
the frequency of malaria transmission, in excess of normal expectancy.Clinical 
endemicity: Endemicity in a given setting can be measured by: 
(i) Spleen rate (SR): proportion of individuals (usually children) with an enlarged 
palpable spleen, per 100 individuals of similar ages 
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(ii) Parasites rate (PR): number of individuals(usually children) with parasitaemia per 
100 individuals of similar ages 
These last two parameters are important considering their impact or incidence at 
different level in different areas, and this is often denoted as: 
(i) Holoendemic: transmission occurs all year long 
(ii) Hyperendemic: transmission is seasonal but intense 
(iii) Mesoendemic: regular seasonal transmission 
(iv) Hypoendemic: very intermittent transmission 
Entomological inoculation rate (EIR), more precise than the previous, is used to 
measure transmission intensity within a given area and it is now considered the gold 
standard by WHO [63]. Nevertheless, it lacks some information especially in setting of 
very low transmission. Therefore, the use of spleen rate and plasmodial rate as 
indicators is justified. Entomological inoculation rate (EIR) is the number of infected-
mosquitoes bites received per person and per unit time(day, week or year). Beier and 
colleagues [64] reported on the relationships between entomological inoculation rate 
and malaria P. falciparum prevalence from 31 sites in Africa (Table 2.2). 
Table 2.1: Relationship between spleen rate, parasitic rate, and EIR and endemicity level in 
children aged 2 to 9 years 
Legend: EIR: entomological inoculation rate 
Zones Spleen rate Plasmodial rate EIR 
Holoendemic >75 >75 >100 
Hyperendemic 50-75 50-75 11-100 
Mesoendemic 10-50 10-50 1-10 
Hypoendemic 1-10 1-10 <1 
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2.4 Genetic Diversity of plamosdium falciparum 
Plasmodium falciparum shows high degree of diversity. This parasite is able to change 
into many different allelic forms of its antigenic proteins while still maintaining the 
biological function. This increases the ability of the parasite population as a whole to 
evade immune responses. Diversity of malaria parasite occurs through random 
mutations when a population undergoes frequent constrictions (i.e. a genetic bottleneck, 
by drug selection pressure) and subsequent clonal expansion [65]. Furthermore, genetic 
recombination occurs in mosquitoes during the diploid short phase following fertilisation. 
When a mosquito ingests gametocytes, from genetically different parasites, meiotic 
recombination favours the exchange of genetic materials (cross- fertilisation) finally 
producing new allelic combinations and haplotypes [66]. High malaria transmission 
areas favour cross-fertilisation where human parasitaemia is frequently polyclonal, 
whereas low transmission areas favour self-fertilisation with offspring genotypes 
identical to parent‟s genotypes [66]. Human population flow also favours genetic 
diversity of parasite population [67].  However, genetic diversity of P. falciparum can be 
reduced by immune (but not always) or drug pressure, which thus selects parasites that 
harbour genes conferring resistance to antimalarials drugs.  Plasmodium  falciparum is 
the most virulent of the five parasites which cause malaria in humans. The inherent 
variability of P. falciparum is particularly prevalent in merozoite surface antigens being 
targeted for malaria vaccines [68]. This provides multiple effective evasion and drug 
resistance mechanisms for the parasite. It also represents a major challenge for 
development of an effective malaria vaccine [69]. Due to the high degree of variation of 
the surface protein, they have been used to assess the genetic diversity of the parasite 
population and also to evaluate antimalarial drug efficacy distinguishing recrudescence 
from reinfection [70] [71].  
Genetic diversity is usually expressed in terms of complexity of infection or multiplicity of 
infection which can be related to endemicity. In effect, the higher the multiplicity of 
infection the higher the number and differences of circulating  P. falciparum genotypes 
and the higher the transmission level.   
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    2.4.1 Immune pressure and evasion of P.falciparum from  
Different parasite clones may vary significantly in immunogenicity, immune-avoidance 
mechanisms, susceptibility to drugs, and transmissibility by different Anopheles 
mosquito vector species. 
Extensive sequence variation is a principal characteristic of P. falciparum as it evades 
host‟s immune system. This evasion is ascribed to the presence of non-synonymous 
polymorphisms found within the genes concerned by these variations (csp, msp, glurp 
described later). The malaria parasite may use repetitive, immuno-dominant epitopes as 
a mechanism to evade the immune response of the human host [72] and many of 
malaria antigens contain tandem arrays of relatively short sequences. It is important to 
recall one of the main properties of the genetic code, which is degeneracy. This means 
that mutations in a codon changes (non-synonymous) or not (synonymous) the encoded 
amino-acid. Maintenance of degeneracy within a repeat set, and the existence of cross-
reacting epitopes in many genes of P. falciparum as a consequence of short repetitive 
sequences and the biased amino acid composition, have been suggested to interfere 
with the normal maturation of high affinity antibodies. The existence of cross reacting 
antibodies has often complicated the problem of identifying specific Plasmodium gene 
products and protective immune responses. In addition, repetitive epitopes may induce 
T-cell independent B-cell activation [73] suppressing antibody production to more 
relevant parts of the antigen.  
Host immune system leads to diversifying selection, which can be measured in terms of 
the ratio of non-synonymous to synonymous single nucleotide polymorphisms (SNPs) 
(pN/pS) [59] [60]. The complexity of the parasite life cycle complicates the development 
of vaccine as at every stage of the life cycle there is an immune response induced with 
a number of antigenic proteins [75]. The expression of these multiple specialized 
proteins during the life cycle is necessary for the parasite to survive in both the 
mosquito and human hosts‟ organisms, as well as for the invasion of different types of 
cells [76]. As noted by Ayala and coluzzi [3] P. falciparum has co-adapted and co-
specialized with Anopheles Gambiae; properties that likely apply in the case of parasite 
and its human host. It seems as demonstrated by mathematical model integrating 
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multiple competing parasite strains of varying virulence subjected to selective immune 
pressure, that the host immune system select for more virulent strain especially in a 
context where immunity is partial [77].  
 
2.4.2 Immunogenicity 
At every stage of the life cycle of malaria parasite there is an induced immune 
response, meaning the implication of different specialized proteins. It is obvious that 
these different responses call for different types of epitopes and single nucleotides 
polymorphisms (SNPs) that can help measuring the immunogenicity (ability of an 
antigen to induce an immune response) of these proteins. Krzyczmonik and colleagues 
[74] analysed series of epitopes and SNPs to compare the immunogenicity across 
developmental stages and different protein classes from Plasmodium. It was found that 
antigenic proteins produced at the sporozoite/stage-specific level were higher in their 
number and were under strong immune pressure as indicated by the pN/pS ratio 
compared to the merzoite for example. This suggests that the immune response 
induced by sporozoites/stage-specific proteins will as well be higher compared to that of 
others. Immunogenicity can also be ascribed to compensatory mutations that when 
selected increase the virulence of the parasite than that of the normal wild type as 
described below in the presence of continuous drug pressure.           
 
    2.4.3 Drug pressure 
Resistance is defined as the ability of a parasite to survive or multiply in the presence of 
concentrations of a drug that normally destroy parasites of the same species or prevent 
their multiplication. Three levels of resistance are defined by the WHO; following 
treatment, parasitaemia clears but a recrudescence occurs; following treatment, there is 
a reduction but not a clearance of parasitaemia and following treatment, there is no 
reduction in parasitaemia [78]. 
Drug pressure is one of those factors that lead to mutation in the malaria parasite. This 
is mainly related to host parasite interactions and development of protective 
mechanisms by the parasites. More specifically, because of deletions, insertions or 
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substitutions in certain genes, single nucleotide polymorphisms (SNPs) have been 
identified in P. falciparum clones which confer resistance to antimalarial drugs. These 
SNPs in many cases are specifically non-synonymous mutations. Drug pressure can 
reduce genetic diversity but not always. As a matter of fact in the presence of drug 
pressure the level of sensitive parasite will decline whereas resistant clones will be 
selected, which complicates the picture of treatment as clones harboring genes 
conferring resistance are of clinical interest [37] [79]. 
Drug pressure can also be detrimental for the parasites in that it inserts mutations that 
are deleterious for the parasite metabolism as it has been found with resistance to 
antifolates whereby, mutations at codon 108 and 59 reduce the affinity of the enzymes 
reductase and synthase enzymes for their natural substrates [80]. Nevertheless, under 
long term drug pressure some mutations qualified as secondary mutations can surface 
and complement for the fitness cost due to primary mutations. These secondary 
mutations like in the case of HIV-1 can increase the virulence or the pathogenicity of the 
parasite [28]. Apparently not many of these mutations have been categorized as 
compared to HIV-1. Selection of these compensatory mutations would therefore be 
beneficial for the parasite to live and this is possible only if the population of P. 
falciparum rises to a sufficient amount 1010-1012 that can select for compensatory 
mutations [81]. A phenomenon termed as competitive Inhibition has been proposed by 
Bialasiewicz et al [82]. In the context of high malaria transmission with a greater than 
tenfold differences in the parasitaemia in a mixed infection the species with the greater 
concentration of DNA will be the only one to be detected. It is likely that this competitive 
inhibition may take place for the selection of compensatory mutations.                  
2.5 Molecular diagnosis/genotyping of Plasmodium falciparum 
From a general point of view, the understanding of the epidemiology of a disease has 
been hampered by poor knowledge of the pathogen structures [83]. It is worth noting 
that the pathogenicity or the virulence of many infectious agents depends greatly on the 
type of genotypes involved as these pathogens can be subject to variations of any sort 
(gene polymorphism or sequence variation for example). High malaria transmission 
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areas for example favor cross-fertilization or genetic recombination while low 
transmission areas favor self-fertilization with offspring genotypes identical to parents‟ 
genotypes. Appropriate detection or diagnosis of the incriminated species or strain 
remains capital as this can bias treatment outcomes in the long/short-term. For the 
diagnosis of malaria, specifically designed primers with targeted genes have been used 
to differentiate between human Plasmodium species (speciation PCR). These genes 
are found in either the nucleus, or the mitochondrion or the plastid (apicoplast) of the 
genus Plasmodium and generally before a specific primer is designed, a given gene 
inside one these structures should first have its sequence established [84]. It therefore 
appears obvious and imperative to study the structural organization (genomics, 
proteomics) of a pathogen in order to design tools that will help in diagnosis. As a 
matter of fact Sulaiman and colleagues[83], by studying the phylogenetic relationship 
between cryptosporidium (Apicomplexan) parasites came to the conclusion that the 70-
Kilodalton Heat-Shock Protein (HSP70) gene compared to the 18-Small-Subunit 
ribosomal RNA gene (SSU rRNA) presented several advantages making a better 
marker for genotyping. 
Molecular phylogenetic stands as a way to predict the function of a gene. It is generally 
hypothesized in terms of homology (similarity attributed to descent from a common 
ancestor) that genes with similar sequences will display similar types of functions or 
regulations. Similarity refers to the extent to which two nucleotides or protein sequences 
are related. The extent of similarity between two sequences can be based on percent 
sequence identity and/or conservation.     
 
2.5.1 Structural organization: considerations and implications for genotyping  
Care must be taken in distinguishing malaria infection especially as co-infection cases 
are often misdiagnosed as single, and whereby the related treatment causes rebound of 
one species. The same apply for multiple genotypes infections where selection of 
resistant strains occurs favoring its dissemination [85].   
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One of the principal characteristics of P. falciparum is its capability of evading the 
immune system by eliciting non-synonymous nucleotides polymorphisms (change in the 
encoded amino acids) [3]. Parasites genes that code for antigenic determinants have 
been isolated and characterized and notably chosen for vaccine development. These 
are circumsporozoite protein (csp) encoding surface proteins of the sporozoite, and 
merozoites for msp-1 and msp-2. The glutamate rich protein, GLURP has also been 
characterized. The msp-3 has been used for the genotyping of P. vivax [86]. 
 The merozoite surface protein 1 (msp-1) 
The merozoite surface protein 1 (msp 1) gene is divided into 17 blocks, based on 
analysis of sequence diversity; seven highly variable blocks are interspersed with five 
conserved and five semi-conserved region [87]. A major mechanism for the generation 
of allelic diversity in the P. falciparum msp 1 gene is meiotic recombination in the 
Anopheles mosquito, which is believed to be dependent on the intensity of transmission. 
It is suggested that frequent recombination events between msp 1 alleles intermittently 
generate novel alleles in high transmission areas [68]. This gene is dimorphic in each 
block, and the alleles have been designated as K1 and MAD20 except in block 2, where 
there is a third allele known as RO33 [68]. Several studies have reported that msp 1 
allelic variants fall under three major types; MAD20, K1 and RO33 but their frequency 
varies in different geographical areas, even in neighbouring villages [68]. The three 
alleles establish themselves depending on the presence, type, and number of tripeptide 
repetitions found in the sequence of this block. Block 2 of the msp 1 gene appears to be 
subjected to rapid intragenic recombination, and so is highly polymorphic. 
 The merozoite surface protein 2 (msp-2)  
This gene also known as merozoite surface antigen (msa-2) gene codes for a merozoite 
surface polymorphic glycoprotein that has been widely studied as one of the major 
vaccine candidates [87]. The sequencing of DNA has shown that a single copy of msp 2 
gene has conserved N- and C terminal domains (blocks 1 and 5), two non-repetitive 
variable regions (blocks 2 and 4), and a polymorphic central region (block 3) containing 
variable numbers of tandem repeats, which also vary in sequence and length. Genes in 
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which polymorphism has arisen through intragenic recombination in repetitive segments 
are characterized by repeat motifs with length variability differing between strains [87], 
[88]. Msp 2 has been widely used to characterize P. falciparum field isolates, and some 
authors have reported that it is highly discriminatory and have used it alone to 
characterize P. falciparum populations [89]. However, the use of only one marker, no 
matter how polymorphic it is, would miss variation at other polymorphic loci, and thus, 
almost certainly underestimate the magnitude of multiple infections. Nevertheless, the 
choice of a particular gene marker for typing natural P. falciparum clones depends on 
the question being addressed. Msp 2 alleles, which differ in number and sequence of 
intragenic repeats, can be grouped into two allelic families, FC27 and 3D7/IC (Figure 
2.1) according to the central dimorphic domain as first observed over a decade ago [95]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Structure of the two families of msp-2 gene, 3D7 and FC27. 
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 The P. falciparum glutamate rich protein (glurp) 
This is another antigen considered to be one of the leading malaria vaccine candidates 
[90] Glurp is expressed in all stages of the parasite life cycle in humans, including the 
surface of newly released merozoites. It is highly antigenic with only one allelic family 
and the gene encoding glurp shows polymorphism in geographically different P. 
falciparum isolates [91]. It is a 220 kD protein expressed in the hepatic, asexual and 
sexual stages of the parasite life cycle. The protein can be divided into an N-terminal 
non-repeat region (R25–500 or R0), a central repeat region (R1) and a C-terminal 
repeat region (R2) [90]. Single nucleotide polymorphisms (SNPs) contribute largely to 
the variability of P. falciparum and provide multiple effective evasion and drug 
resistance mechanisms for the parasite necessitating the use of molecular techniques 
to differentiate alleles responsible for recrudescence and re-infection after treatment 
[92]. 
These genetic markers are unlinked, i.e. located on different chromosomes, single-copy 
genes with extensive polymorphism, both with regards to sequence and size, are mostly 
generated by intragenic repeats that are variable in copy number and length of the 
repeat unit. As such they have proven to be useful tools both in molecular epidemiology 
studies in different epidemiological settings as well as to distinguish treatment failures 
from new infections in antimalarial drug trials [68]. Other genes found in P. falciparum 
genome are microsatellites genes and resistant genes. The latter will be discussed 
below.  
Study the polyclonality (using polymorphic markers) of P. falciparum population is of 
great clinical interest as minority clones may harbor genes conferring resistance to 
antimalarial therapy that can be selected and therefore contributing to treatment failure 
[79]. This analysis permits to distinguish between recurrent infections and new 
infections in clinical trials of antimalarials drugs by using the so called PCR-correction. 
However this technique (PCR genotyping) has shown drawbacks in that the population 
of minority clones is underrepresented [93]. These drawbacks lead to misclassification 
of PCR data in clinical trials and underestimation of the extent of allelic polymorphism in 
any given infection [94]. A powerful and robust technique, genome sequencing, has 
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been proposed and used to circumvent these limitations [93]. The authors concluded 
that the technique provide high quality data useful for drug resistance studies, and 
robustly represents clonal multiplicity.      
2.5.2. Molecular Phylogenetic as a way to predict resistance patterns or spread 
As previously mentioned, phylogenetic can help to predict (inference) the function of a 
given gene after this gene has been aligned with a reference gene. This is how some 
genes or species have been classified as mutant types with respect to the wild type 
(reference type). The use of molecular systematic has permitted to classify variants of 
species on the basis of their sequence homology, which also determines their severity 
in disease development. This has been the case with the human papillomavirus (HPV) 
that causes cervical cancer. On the basis of their homology it was found that the HPV16 
and 18 are highly oncogenic compared to others, less oncogenic.[95] 
The spread of antimalarial resistance since its evolution is worrisome especially 
knowing that the new medication or ACTs are at stake. Indeed some ACTs 
(Sulphamethoxypyrazine-pyremithamine/Co-Arinate®) have as partner drugs 
sulfadoxine or pyremithamine which resistance has been reported in many instances 
when coupled to amodiaquine or not [32] [96]. Resistance to ACTs has been reported in 
Asia, Thai-cambodia and in some areas in Africa and the spread of resistance is matter 
of debate among the scientific communities. Understanding the spatial clustering of 
Plasmodium falciparum populations can assist efforts to contain drug-resistant parasites 
and maintain the efficacy of future drugs (Taylor et al., 2013). These authors have 
demonstrated using microsatellite markers, proven to be more sensitive than other 
markers [97], that populations in the West manifested dhps mutant (resistant) 
haplotypes with independent lineages and with single-mutant SGKA and AGKA 
haplotypes. Compared to the East these haplotypes were largely unrelated to the 
double- and triple-mutant SGEA and SGEG. The authors suggested that there is 
significant barrier to parasite population flow between the East and the West of 
Democratic Republic of Congo and P. falciparum sulfadoxine resistance is 
geographically and genetically clustered within the DRC. Another study of the same 
kind but not confined to one country in 2009 studies the evolutionary origins of dhps 
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mutations [14]. The latter characterized five major lineages with the geographical 
distribution of dhps resistant alleles mutations: SGK (Serine-Glycine-Lysine), AGK 
(Alanine-Glycine-Lysine), and SGE (Serine-Glycine-Glutamate), wild-type alleles AAK 
(Alanine-Alanine-Lysine) and SAK (Serine-Alanine-Lysine). The authors suggested that 
there has been dispersal throughout west and central Africa from their original foci, with 
Cameroon at the confluence of west, central, and southwest African gene pools. These 
findings show that sulfadoxine-resistant P. falciparum has recently emerged 
independently at multiple sites in Africa and that the molecular basis for sulfadoxine 
resistance is different in east and West Africa. This latter result may have clinical 
implications because it suggests that the effectiveness of sulfadoxine as an antimalarial 
drug may vary across the continent. Furthermore, these findings suggest that economic 
and transport infrastructures may have played a role in governing recent parasite 
dispersal across the continent by affecting human migration. Thus, coordinated malaria 
control campaigns across socioeconomically linked areas in Africa may reduce the 
African malaria burden more effectively than campaigns that are confined to national 
territories. 
2.6 Anti Malarial Efficacy and in vitro and in vivo tests  
Several methods for monitoring antimalarial drug efficacy exist; they include in vivo and 
in vitro tests and, more recently, molecular markers. In vivo tests are traditionally the 
“gold standard” method for detecting drug resistance (WHO, 1996). Standardized by 
WHO these tests reflect the biological nature of antimalarial treatments. Malaria patients 
are selected, and monitored clinically and biologically for 28 or 42 days after the 
treatment regimen received. These longitudinal studies measure the incidence of 
malaria in the real world. The incidence of treatment episodes is an outcome that is 
highly relevant to public health policy makers, as it reflects not only the burden of 
disease but also the utilization of health resources. 
 The advantage of the in vivo tests over the in vitro assays is that they can be 
conducted in the field with little equipment and personnel and the results are easy to 
interpret. They reflect the true biological nature of treatment response, which involves a 
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complex interaction between the parasites, the drugs, and the host response, while in 
vitro tests measure only the interaction between the parasites and the drugs. Although 
the information gained from in vivo studies is exactly what is needed to make rational 
and evidence-based malaria treatment policies, standard in vivo studies remain 
expensive and time-consuming, and longitudinal clinical efficacy trials are even more 
so.  
In vitro assays are based on the inhibition of the growth and development of malaria 
parasites by different concentrations of a given drug relative to drug-free controls. As 
many countries resort to combination therapies to increase treatment efficacy and delay 
the emergence of drug-resistant parasites, monitoring the efficacy of individual 
components in drug combinations by in vitro drug sensitivity assays and molecular 
markers is helpful [98].The in vitro testing plays a role in detecting the early stages of 
resistance and has become a complementary tool for the surveillance of drug 
resistance. In vitro assays have the advantage of yielding objective results of parasite 
responses to drugs without any interference of host factors, including pharmacokinetics, 
acquired immunity, and patient compliance with therapy. The variations in parasite 
density and haematocrit (the inoculum effect) as well as the stage-dependent action of 
antimalarial drugs must be controlled because they cause a significant impact on the 
outcome of these assays [99].  
Parasites are cultured in erythrocytes in the presence of RPMI 1640 media added to 
already dose 96 well plates. Assays are run in duplicate for each drug, and placed in a 
candle jar at 37ºC for 72 hours. In vitro drug sensitivity tests are all based on 
measurement of the effect of drugs on the growth and development of malaria 
parasites. These are parameters that can be measured in several different ways and 
each has exceptional characteristics. Parasite growth in drug-exposed cultures is 
measured relative to drug- free controls. When performed with serial dilution of drugs, 
these tests will result in sigmoid dose-response curves. These sigmoidals curves 
sometimes permit to evaluate the synergistic and the antagonistic effects in terms of 
isobolograms. However, in vitro assays have several problems and drawbacks. (i) They 
require highly skilled personnel and laboratory equipment. (ii) Parasites isolated from 
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patients who have taken medication on their own initiative a few days before 
consultation usually do not grow in vitro (iii) there is no consensus about the 
determination of the threshold Inhibition Concentration IC50 that distinguishes 
susceptible from resistant parasites.  
Consequently, in vitro tests provide little information on the efficacy of the drug. There is 
poor correlation between in vivo and in vitro test results, especially in areas of intense 
transmission, presumably due to the influence of host immunity. The accuracy of the 
inhibitory concentrations for a given sample is also influenced humoral factors from the 
donor that can interfere with parasite maturation [100]. Despite these shortcomings, in 
vitro tests are of value, particularly for testing parasite resistance to new drugs and 
agents that have not been used previously. They can provide important longitudinal 
data on changes in parasite response to drugs, which is important collateral information 
about the emergence and spread of drug resistance. Methods of in vitro drug sensitivity 
assays include the following: WHO microtest, isotopic (tritiated hypoxanthine uptake) 
assay, lactate dehydrogenase (pLDH), histidine-rich protein 2(HRP2), SYBER Green I 
and other fluorescent dyes. 
The limitations of in vivo and in vitro methods for measuring drug-resistant malaria and 
the elucidation of molecular mechanisms of resistance to some antimalarial drugs have 
led to considerable research on molecular markers for resistance. A number of 
techniques based on molecular amplification of regions in the parasite genome that are 
different between species, strains and resistant types have been envisaged. 
2.7 Factors affecting Anti malarial Efficacy and Parasite clearance 
      2.7.1 Human factors (age, immunity)  
Genetic diversity is thought to be influenced by age due to variability of acquired 
immunity in the population whereby acquired immunity is absent in new born children 
and only acquire partial immunity six months later which is fully developed in adulthood. 
Till date there is no consensus on the distribution of P. falciparum genetic diversity 
related to age. As immunity increases parasite counts are lower, severe malaria is less 
common, and parasite clearance is accelerated. In endemic areas this is reflected in the 
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differing clinical presentations and therapeutic responses with increasing age. 
Conversely as immunity declines, for example if transmission is reduced, then parasite 
clearance rates reduce [101]. Naturally acquired immunity has been found to accelerate 
parasite clearance in response to artesunate and the half-life decreases with age [102]. 
This parasite clearance is mediated by immunoglobulins IgG that recognize parasitized 
red blood cells (RBCs) (opsonisation) and have the ability to block cytoadherence or 
sequestration of parasites. The proportion of IgG was found to inversely correlate with 
the ½ life of parasite clearance and in an age dependent manner [15] in children in Mali. 
In fact, artemisinins half-life decreased by 4.1min for every one year increase in age.  
A study published in 2011 [103] investigated on the relationship between host candidate 
gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites 
across five large association studies from Burkina Faso, Cameroon, Kenya, Mali and 
Sudan. Among the 70 SNPs investigated and after adjustments for confounding factors 
such as age and ethnicity and gender only three polymorphisms were significantly 
associated with clearance phenotypes of drug-resistant parasites. These 
polymorphisms were related with the genes coding for interferon regulatory factor 1 (AC 
or CC genotypes), interleukin 4 receptor gene IL4R (TT or TC), the Der1-like domain 
family gene Derl3 (AG or GG).  
It is generally known that in endemic areas children under five years old are the most 
affected because of the immune system not yet fully developed. In the other hand it has 
been suggested that children under six months have a lower incidence of severe 
malaria compared to older ones because of the presence of antibodies acquired 
through breast-feeding (probably Immunoglobulins). Maternal milk lacks PABA which is 
required for the malaria parasite metabolism [20] 
In endemic settings individuals are mostly exposed to mixed malaria parasites co-
infections. Coinfection with P. falciparum and P. malariae has been reported in 
Bangolan, North-West region of Cameroon (Achonduh et al. manuscript submitted) 
among women and, children as from 2months. Most of these populations had 
asymptomatic malaria. Plasmodium falciparum dynamics or pathogenicity has been 
reported to be modulated (decrease parasitaemia) by the mild infection P. malariae 
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through non-specific and cross-specific immune response [104]. Clearly, P. falciparum 
population is reduced (competitive inhibition). Conversely [105] reported that P. 
malariae do instead increase P. falciparum gametocytaemia, which in this case may 
raise concern with regard to the spread of the most dangerous of human malaria 
parasites. It is not however well described whether this decrease or increase in P. 
falciaprum asexual or gametocytes is age dependent.            
2.7.2 The implication of Pharmacogenomics and polymorphism: Principles   
The quantitative role of enzymes responsible for drug metabolism, the kinetics of the 
drug and its „‟therapeutic window‟‟, help determine how to adjust drug dose in poor 
metabolisers or ultra-fast. Not knowing the genotype or phenotype of the patient who is 
administered  a standard drug dose may result in overdose in slow metabolisers and will 
be more likely to develop toxicity, while ultra-fast metabolisers are under-dosed. 
Another situation is where the therapeutic effect depends on the formation of an active 
metabolite, so we do not observe the therapeutic response in poor metabolisers, while 
we observe an amplified response in ultra-rapid metabolisers [106] Recently several 
drugs have been withdrawn from the market because of severe side effects associated 
with taking them.. 
 Pharmacokinetics and polymorphisms 
When drugs enter the body, their destiny is determined by the absorption, distribution, 
metabolism and elimination steps. The majority of pharmacogenetic differences have 
been characterized at the molecular level until now for genetic variations in enzymes 
responsible for drug metabolism. The pharmacokinetics was then the first field of clinical 
research to apply pharmacogenomics and is currently the most active in this regard. 
 Phase I enzymes  
Phase I metabolism is the functionalization phase reactions involving oxidation, 
reduction and hydrolysis of xenobiotics. Most enzymes involved in the metabolism and 
elimination of drugs are part of the cytochrome P450 (CYP450). However, many 
examples of polymorphisms are found in these enzymes [107].  
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 Phase II enzymes 
Phase II metabolism in the conjugation phase for glucuronidation reactions, sulfonation 
and acetylation. N-acetyltransferase type 2 (NAT2), was one of the first phase II 
enzymes discovered as polymorphic. Indeed, pharmacogenomic differences in NAT2 
gene (encoding the N-acetyltransferase type 2), are responsible for a metabolic 
polymorphism at the N-acetylation of primary metabolites and induce two groups of 
individuals having two phenotypes: the rapid acetylators and slow acetylators. Other 
enzymes of phase II metabolism are: glucuronosyltransferases (UPDGTs), glutathione-
S-transferases (GSTs), sulfotransferases, the thiopurine methyltransferase (TPMTs) are 
also polymorphic [107]. 
 Metabolism of phase I and phase II enzymes 
The frequencies of genetic variations depend on ethnic populations. It is therefore 
essential to consider the ethnic characteristics to improve the diagnosis and care of 
patients by providing information on the structure of genes and regulatory pathways that 
can lead to impaired response. The potential consequences of polymorphisms in drug 
metabolism can be: a prolonged pharmacological effect, side effects, lack of activation 
of the pro-drug toxicity, an increase in the effective dose, drug interactions exacerbated. 
Indeed, the genetic variability of expression levels or function of these enzymes has a 
very important impact on the effectiveness of the drug [107].  
o N-acetyl transferase 2 gene 
The enzyme N-acetyltransferase 2 (NAT-2) is involved in Phase 2 of the 
biotransformation of xenobiotics and catalyzes the transfer of an acetyl group from 
acetyl coenzyme A to certain drugs and other xenobiotics with arylamine structure [108]. 
Therefore, the active enzyme detoxifies drugs such as isoniazid, anti arrhythmic drug 
proainamide (PA), anti-inflammatory drug 5-aminosalicylic acid (5-ASA), and dapsone, 
a drug used for the treatment of malaria. 
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o Chromosomal Location of NAT2 gene 
The NAT2 gene has 36 alleles and is found in the liver of adults. It is located on the 
chromosome pair N0 8 [109]. 
o Regulation of expression of the NAT2 gene 
 Rather et al.[110] have shown by cloning the NAT2 gene that transcription begins at 
the initiation site (G) in position 233 Pb, and the recognition sites are located in the 
promoter -10 (TATAAT) and -35 ( CTTTTT). The transcript of this gene is induced by 
xenobiotics [110]. 
o NAT2 gene polymorphism 
Longuemaux and colleagues [109] have shown using RFLP-PCR that the NAT2 gene 
contains 36 alleles and in these alleles come first, haplotype variations of seven 
mutations (G191A, T341C, A434C, G590A, A803G, A845C and G857A) and five silent 
mutations (T111C, C282T, C481T, C759T and A803G), 2 substitutions (single-
nucleotide), G499A and C190T. 
The wild-type allele NAT2 designated NAT2*4 does not have a mutation and is 
associated with rapid acetylation. NAT alleles NAT2*5 such as, NAT2*6, and 
NAT2*7*14 NAT2 respectively containing mutations G191A, T341C, A434C and / or are 
associated with G590A slow acetylation. Alleles associated with rapid acetylation are: 
NAT2*11, NAT2*12 and NAT2*13. The allelic polymorphism of the NAT2 gene is also 
based on ethnicity. The different types of NAT2 genotypes are given in Annex 1. 
        2.7.3 Ecological Factors (ethnicity, endemicity, climate)  
Ethnicity has been shown to have an impact on resistance or susceptibility to malaria. 
The genetic background (lactase persistence) related to their diet has made the Fulani 
tribe to be resistant to malaria compared to the Dogon tribe who consumes less cow 
milk than the Fulani do [20]. Milk diet is less rich in P-aminobenzoic acid (PABA), which 
the parasite needs for its metabolism. In the absence of this, the parasite synthesizes 
PABA de-novo which still, seems not to be sufficient in the context of Fulani tribes and 
therefore the parasite is easily suppressed.  
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It has been found that ethnicity may also have a major impact on drug metabolism and 
hence drug efficacy and safety. Differences in ethnicity have a deep impact on drug 
clearance due to pharmacogenetic polymorphism in drug metabolizing enzymes and 
transporters, or drug targets. Alterations in clearance can have an impact on safety, 
efficacy and dosing regimen. Certain enzymes polymorphism associated with enhanced 
or decreased drug metabolism has been characterized with frequencies and types 
varying among ethnic groups [18]. The latter analysed a series of alleles polymorphisms 
in genes encoding enzymes involved in the metabolism of antimalarials, namely the 
cytochrome (CYP) P450 isoenzymes and NAT-2 genes in samples from Cambodia and 
Tanzania, two different ethnic groups. It was suggested that the CYP3A4*1B allele 
frequency between the two populations presents a potential explanation for the lower 
efficacy of arthemeter-lumefantrine (AL) in Cambodia.   
Endemicity as mentioned earlier plays a role in the development of acquired immunity 
and the increase of parasites population dynamics with the consequence on sensitive or 
minority undectable clones that may harbor genes conferring resistance. More so in 
high endemic areas people tend to be infected with more than one parasite, which 
coinfection can modulate the effect of the strongest by lowering is peripheral blood 
density. Malaria intensity is in the other hand favored by factors such as climate, high 
atmospheric humidity and social environments or urbanity. These factors in one way or 
the other facilitate the spread of the disease.  
Climate or vegetation favors breeding sites for mosquitoes, which vectorial capacity can 
be such that more virulent parasites can be transmitted [2]. For the disease to be 
transmitted the vector survival should be long enough because it is currently affected by 
the virulence (apoptosis) caused by the parasite [62]. In low transmission areas it was 
found that P. falciparum genotypes that are highly diverse clustered with the rainy 
season confirming the seasonal distribution of P. falciparum genotypes [111]. Most 
importantly to consider here is the possibility of mosquitoes to transmit parasites that 
harbor resistance genes and is of concern today to see how much measures are being 
deployed to study the evolution and the spread of resistance as proposed by some 
phylogenetic and phylogeography studies. 
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2.7.4 Parasite factors (resistant genes, life cycle)  
These are useful tools that complement phenotypic assays for drug resistance. They 
also guide the design of strategies to avoid such resistance once it has reached levels 
of clinical significance. Molecular markers theoretically offer the earliest way to detect 
emerging drug resistance and intervene accordingly, since they examine fundamental 
processes in the resistance pathway. 
 Mutations in the dhfr gene and resistance to pyrimethamine 
In vitro resistance to pyremithamine is almost always associated with Ser108Asn 
domain mutation of DHFR [112][113]. Levels of higher in vitro resistance result from 
sporadic mutations at codons Asn51Ile, Cys59arg and / or Ile164Leu. The association 
between the phenotype of in vitro resistance to pyrimethamine and DHFR genotype has 
been demonstrated by studies of site-directed mutagenesis and transfection 
experiments. However an alternative mutation causing replacement of a serine by a 
threonine at codon 108 with a change of an alanine to valine at position 16 may provide 
a specific resistance to cycloguanil [112][113]. Sequencing of pvdhfr gene in 
Plasmodium vivax showed mutations at position 58 and 117 of the DHFR protein in 
parasites resistant to pyrimethamine and cycloguanil. These amino acid changes were 
similar to changes observed in the DHFR protein of P. falciparum, respectively with 
arginine at position 59 and asparagines at position 108.  
Recent studies have shown that pyrimethamine and cycloguanil are significantly less 
active vis-à-vis the mutated forms of DHFR in P. vivax [112] These results confirm the 
results of work on the kinetics of enzyme inhibition of DHFR in P. vivax. The affinity is 
reduced between mutations of Ser58Arg and Ser117Asn of pvdhfr and two antimalarial 
drugs, pyrimethamine and cycloguanil. This may be the cause of resistance to antifolinic 
in P. vivax. 
 Mutations in dhps gene and resistance to sulfadoxine 
In the same way of in vitro resistance to pyrimethamine, resistance to sulfadoxine 
appears to be associated with Ala437Gly point mutation in field study of DHPS. 
However, higher levels of resistance to sulfadoxine are associated with additional levels 
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of codons Ala586Gly, Ser436Phe and Ala613Ser [114], [115].However an additional 
mutation at codon 540 is correlated with increased levels of resistance to SDX-PYR 
association [116]. 
 Mutations in the Pfdhfr and pfdhps genes and resistance to sulfadoxine-
pyrimethamine combination (Fansidar ®) 
Fansidar ® became the first-line drug for the treatment of uncomplicated malaria in 
Africa after emergence of chloroquine resistance but its effectiveness was short, only 5 
years in South East Asia, South America and Africa [37], [114]. Extension of CQ-R to P. 
falciaprum, led to the increase use of SDX-PYR combination in the treatment of 
uncomplicated malaria in many countries in Africa [114], [117]. In the case of SDX-PYR 
combination, these multiple mutations in two genes contribute to resistance in vitro of 
these two molecules, namely SDX and PYR, taken separately. It appears difficult to 
establish a series of mutations necessary and essential that cause resistance to the 
combination of these two molecules. 
Thus, Gly-437 mutations followed by Glu-540 are frequently encountered as associated 
with resistance to SDX-PYR [118]. However, the risk of treatment failure with only one 
triple mutation 108, 51 and 59 at the PfDHFR gene is low. The targets genes for SDX 
and PYR are respectively, DHFR and DHPS. Sulphadoxine inhibits dihydropteroate 
synthase (dhps) gene, whereas Pyremithamine inhibits dihydrofolate reductase (dhfr) 
gene in the folate pathway of the parasite. This combination acts in synergy. These 
mutations alter the configuration of the active site and consequently reduce the affinity 
for active compound.  
 We might think that mutations in either of these two genes could be the cause of 
resistance to the association SDX-PYR, but studies have shown that mutations in the 
Pfdhf gene seems to appear first, followed by mutations on pfdhps gene. Thus, 
mutations in the pfdhps gene appear in parasites with a double or triple mutation in their 
gene Pfdhfr selected by the presence of pyrimethamine  [119]. Similarly, mutations at 
codons 437, 540, 581 of pfdhps were mainly observed in areas where prevalence in 
pfdhfr mutations is high. 
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 Genes involved in resistance to chloroquine, quinine, mefloquine and 
halofantrine 
o Genes involved in resistance to chloroquine 
The late appearance of chloroquine resistance in P. falciparum suggests a mechanism 
in which the molecular basis is more complex than the acquisition of a few point 
mutations as observed for genes involved in resistance to anti-metabolites. Indeed, the 
results of several studies have shown a multifactorial mechanism that requires 
simultaneous mutations on several genes located independently of each other on 
different chromosomes of P. falciparum. These are the pfmdr1 genes pfmdr2, pfcg2 and 
pfcrt. 
 pfmdr1 and pfmdr2 genes 
Efflux and or lack of accumulation of amino-4-quinolines, by analogy to the mechanism 
of resistance in cancer cells, were suggested in 1990 ([120]). The phenotype MDR 
(multidrug resistant) of cancer cells was described for the first time in 1970 by Riehm 
Biedler who observed the occurrence of simultaneous cross-resistance to anticancer of 
several chemicals after selecting one resistant line of cancer cells to one class of 
anticancer. MDR is associated with the decrease in the intracellular accumulation of 
anticancer drugs as well as resistant cells expressing the P-glycoprotein encoded by the 
MDR [121] gene. Several observations showed a similar mechanism for 
chemoresistance in P. falciparum as accelerated efflux and / or slowed chloroquine 
accumulation in chloroquine-resistant parasitized red blood cells (pRBCs) rather than 
chloroquine- sensitive strains. Initially, it was assumed that changes in pfmdr1 genes 
and pfmdr2 were related to resistance to chloroquine. This has not been confirmed and 
instead assumes the involvement of other genetic and molecular factors. No correlation 
was found between alleles of these two genes and chloroquine resistance in studies of 
isolates from Sudan. Field studies have shown many exceptions regarding the idea of 
an association between pfmdr1/2 point mutations or 2 and CQ-R. However, 
amplification of pfmdr1 has been associated with resistance to mefloquine in in vitro 
studies[121]. These studies also showed that the pfmdr2 gene is neither mutated nor 
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amplified and its expression in sensitive or resistant parasites is not different, which 
reduces its role in resistance to antimalarial drugs. Other studies have shown a 
significant association between amino acid 86 of the pfmdr1 gene and CQ-R [122]and 
there is a correlation between in vitro response and resistance gene pfmdr1 in only 68% 
cases [123]. These results show that the codon 86 of the pfmdr1 gene may not be a 
suitable molecular marker to assess the CQ-R and requires the involvement of other 
codons of the pfmdr1 gene, but other studies have not shown their implication in the 
resistance [124]. However,  the relation between the pfmdr1 gene and CQ-R suggests 
the implication of other genetic factors in P. falciparum. 
 The gene pfcg2 
Many studies have located the genetic locus governing CQ-R in a region of 400 kb on 
chromosome 7 of P. falciprum [124]. An extensive study on a restricted area of 36 kb of 
this locus by using a greater number of RFLP and microsatellite markers identified 
among the eight potential genes in this locus, polymorphism in the cg2 gene. The Cg2 
gene encodes a transmembrane protein of 330 kDa, localized in the membrane of the 
food vacuole and in the plasma membrane of P. falciparum [125] However, other 
studies have shown that the relationship between cg2 polymorphism and CQ-R is 
strong but not absolute, suggesting the possible contribution of other genes in the 
resistance. 
 The pfcrt gene 
A more detailed analysis of the locus of 36 kb including cg2 gene revealed the pfcrt 
gene (chloroquine resistant transmembrane protein) consisting of 13 exons. This gene 
is located on chromosome 7 as cg2. Complex and polymorphic, pfcrt is absolutely 
linked to the CQ-R [126]. The pfcrt gene product is a transmembrane protein (integrin), 
it could play a role as a carrier of chloroquine. Many in vivo and in vitro studies have 
shown since 2000 that there is a correlation between the K76T mutation and CQ-R 
[127] [126] [124]. These studies have shown that whenever there is a treatment failure, 
there is an absolute selection of the mutant allele of the gene pfcrt K76T among most 
children with the mutant allele with an adequate clinical response to chloroquine [124]. 
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This discrepancy observed in other studies is probably due to the polyclonality of most 
infections [93]. However, in areas where there is a high rate of CQ-R, the mutant allele 
of the gene pfcrt is ubiquitous and this does not seem to affect the clinical response of 
the immune individuals for which chloroquine is an effective treatment and where there 
is complete parasite clearance. All these studies show that the gene pfcrt may be a key 
determinant in the phenotype of resistance or sensitivity to chloroquine. The 
combination genotype pfcrt-resistance phenotype is more evident in vitro than in vivo 
studies, however, the correlation between pfcrt and CQ-R in vitro is not perfect because 
either the polyclonality [30]or because of the influence of multiple mutations in the pfcrt 
gene on the phenotype of the CQ-R. Eleven codons of crt protein can mutate in a CQ-R 
parasite [126]However, mutations in the gene pfcrt generally form a single haplotype in 
Asia and Africa. A different genotype from those determined so far has been observed 
in a native South American strain, New Guinea [123]. 
 
 Role of P-glycoprotein homologue Pgh1 the Resistance 
Protein P-glycoprotein belongs to the family of ABC transported. It is overexpressed in 
MDR cells and act as efflux pumps cytotoxic drugs. Several observations showed that a 
similar mechanism could be at the origin of drug resistance in P. falciparum as efflux 
accelerated and / or decelerated chloroquine in erythrocytes parasitized by a CQ-R 
strain, but not by a CQ-S strain accumulation. Modulation of the CQ-R by verapamil 
calcium channel blocker partially reverse drug resistance in neoplastic cells (Martin et 
al., 1987). The presence in P. falciparum of a homologous gene to MDR cancer cells, 
called pfmdr1 gene [126]or the detection of P-glycoprotein parasite called pgh-1 [112] 
was associated with CQ-R.  
Aside from genes conferring resistance that harbour some parasites clones some 
factors by „‟virtue‟‟ of the nature and intrinsic to the parasite may account for the 
decrease of parasite clearance. Decrease in P. falciparum population has been reported 
in the context of mixed infection with P. malariae. The latter modulates the dynamics of 
P. falciparum population through non-specific and cross-specific immune response 
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[104]. The intrinsic characteristic related to parasites here can be explained by the 
capacity or the ability defined in its immunogenicity property of the parasite to trigger 
specific immune response. P. malariae and P. falciparum are different in that, P. 
malariae can be eliminated by P. falciparum-specific effectors, but is unlikely to activate 
or stimulate proliferation of P. falciparum-specific effectors. The possibility of cross-
immunity here is offered by the degree to which both share epitopes but in the limit of 
effectors stimulation or activation [104]. The model (blood-stage dynamics of a mixed-
species malaria infection) that explained these mechanisms is based on the 
consideration of the prepatent period of P. falciparum and P. malariae. In facts the 
model showed that at least 25 days are required to greatly suppress P. falciparum. In 
another instance using a dynamic model integrating the dynamic of P. falciparum and P. 
vivax coinfection and the effect of antimalarial [85] it was demonstrated that when the 
infection is misdiagnosed as P. vivax single infection treatment for P. vivax can lead to a 
rapid surge of P. falciparum. This finding as suggested by the authors can be applicable 
in the case of mixed-genotypes (drug susceptible and drug reistance) whereby following 
treatment resistant genes can be selected and easily spread.      
Understanding the complexity of human malaria parasite life-cycle is of key interest as 
drugs are specifically designed to target specific parasite stages. Parasite clearance 
time can be influenced by factors related to the parasite itself. For example it is well 
known that artemisinis derivatives target the ring-stage but it is not well understood how 
this is possible for mature ring-stage parasites that have the ability to sequester to 
organs [101] [15]. 
When parasitized red blood cells (pRBCs) rupture at schizonts/mature trophozoites 
stage, the plasmodials antigens released stimulate the lymphocyte Th1, which secretes 
interferon IFN-γ. INF-γ and malaria toxins Glycosylphosphatidylinositol (GPI), released 
on merozoites rupture, activate the macrophages that secrete cytokines (TNF-α, IL-1, 
IL-6). These are responsible for many of the signs and symptoms including paroxysms 
[128] TNF alpha concentation > 100 pg/ml of serum is highly associated with cerebral 
malaria and death [129]. Another toxic product is the malarial pigment haemozoin 
produced by the polymerization of heme, a by-product of host haemoglobin proteolysis 
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by the malaria parasite. Haemozoin is known to severely inhibit the function of 
monocytes and macrophages after its ingestion [130]. The above-cited cytokines have 
double effects. Firstly, their parasiticide action facilitates parasites clearance at low 
concentration [128] either immediately or by the intermediate of free oxygenated 
radicals or nitric oxide (NO). Secondly, the cytokines stimulate endothelial cells of 
capillaries and cerebrals post-capillaries veinules, which express adhesion molecules 
like ICAM-1, VCAM-1, and E-selectine. These molecules later on interact with the 
parasite ligand, Plasmodium falciparum ertythrocyte membrane protein1 (PfEMP-1), 
expressed at the level of protuberances (Knobs) of parasitized red blood cells (pRBCs), 
facilitating adhesion of pRBCs with an attempt to escape host immunity system 
(destruction by the spleen), therefore disappearing from the peripheral blood (Figure 
2.2C). However, there is a possibility for these pRBCs of trafficking in other blood 
vessels where sequestration is not possible probably due to the presence of some 
antibodies that target the pfEMP1. These antibodies then prevent sequestration by a 
mechanism known as opsonisation, meaning that pRBCs are labelled by these 
antibodies for phagocytosis in the spleen (Figure 2.2B) (Beaudry et al. 2011). These 
antibodies may contribute to the clearance of ring-stage parasites, a process which 
does not depend on artemisinin clearance in the context of artemisinin treatment. 
Dihydroartemisinin (DHA), the active metabolite of all artemisinins, causes ring-stage 
parasites to undergo pyknosis (Figure 2.2A). This mechanism is possible by the 
production of free radicals from enoperoxide that alkylate and oxidize the proteins and 
lipids of intraerythrocytic parasites [132]. These circulating pyknotic forms are eventually 
“pitted” from red blood cells (RBCs) as they pass through endothelial slits in the spleen, 
which returns the previously infected, intact RBCs to the peripheral blood [133]. This 
process occurs in all patients treated with artesunate and is likely the predominant 
mechanism of parasite clearance in most cases.  
 
 
 
46 
 
 
 
Studies have also been carried out for resistant parasites clearance time [134]. The 
authors found that chloroquine resistant parasites carrying the K76T mutant allele are 
cleared in an age dependent manner suggesting the implication of key genetic or 
immunity elements that still need to be identified. As stated earlier IgG and IgM to be 
part of the immune elements contributing to the short parasite clearance time reported 
after artemisinin treatment [15].  
 
 
 
 
 
Figure 2.3: Clearance of ring-stage Plasmodium falciparum parasites from peripheral blood during a parasite 
clearance rate study. 
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Chapter 3: Materials and Methods 
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3.1 Research Design 
The study design was a 3-arm, open, randomised controlled trial.  A total of  720 
children of either gender, with acute uncomplicated P. falciparum infection, who fulfill all 
of the inclusion and have none of exclusion criteria, and provide signed informed assent 
(by at least one parent or legal guardian) were enrolled in the study (appendix I). 
Enrolled patients were randomised to receive the three treatment, i.e, Study Arm-A: 
artesunate-amodiaquine, Study Arm-B: dihydroartemisinin-piperaquine and Study Arm-
C: artemether-lumefantrine at the ratio of 2:2:1. Patients administered treatment by 
directly observed treatment (DOT) by the study nurse during a  3-day period and full 
clinical and laboratory assessments and observation of early adverse effects were 
assessed. On treatment completion after the third day, participants were required to 
report to the study clinic on days 7, 14, 21, 28, 35 and 42 or at any other time when 
clinical sign(s)/symptom(s) of malaria is suspected.  Those who failed to keep these 
follow up appointments were visited by a community health worker. Appendix II 
summarises the activities during recruitment and follow-up.  During the first three days, 
the study clinician made a clinical assessment of the patient once  a day and recorded 
all observations in the Trials Register and Hospital Patient File before transfer into the 
case report form (CRF).  Blood smear for examination of parasitaemia, haematology 
and biochemistry were investigated during follow up and/or on the day of reappearance 
of parasitaemia (recrudescence/reinfection).  
  3.1.1 Study population 
 Description of Study Population 
Children of either gender, aged between 6 months (> 5kg) and 10 years, with acute 
uncomplicated falciparum malaria were recruited from the outpatient clinics of 
participating health facilities. The study population was selected from malaria positive 
patients during routine practice at the study sites.  
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- Study Sites 
The study was conducted at two geographically distinct sites, i.e.,  Mutengene (Littoral-
Forest) and Garoua (Sahel-savanna).  These sites fall within two of the three major geo-
ecological zones of Cameroon as described by MARA maps [22] 
Mutengene is situated at coordinates 04o01‟N, 09o11‟E.  The climate is equatorial with a 
rainfall of 10,000 mm per annum and a temperature average of 25oC. The vegetation is 
semi-mangrove and tropical wet forest.  The study site is limited to the south and south-
east by the sea and to the north and north east by mount Cameroon, an active volcano 
that is 4,100m above sea level. The population works predominantly on palm and 
rubber estates that are owned by the Cameroon Development Corporation (CDC). 
Garoua is in the North of Cameroon and lies at the coordinates, 06o24‟N, 10o46‟E.  
Garoua serves as a river port in years when the rainfall is abundant.  Situated in the 
river Benue basin,  it receives an average annual rainfall of 380 mm.  It has about 4  
months of rainy season. Temperature here averages about 31oC for most of the year 
and the vegetation is guinea-savannah.  The population is predominantly Muslim and is 
comprised mainly of cattle raisers.  A few have taken to trading with neighbouring 
Nigeria. 
 Sample Size Estimation 
Assuming that artesunate-amodiaquine was successful (cure rates) in above 94% of the 
patients, then p was set at 94%. To demonstrate  with  95% confidence ( = 0.05) that 
artesunate-amodiaquine or dihydroartemisinin-piperaquine was acceptable if they are at 
worst 10% (d) inferior in the occurrence of failures, we would accept a 10% risk ( ) or 
(90% power) to rule out the null hypothesis of the lack of inferiority.  
Using the formula with f(, ) statistics[135]: 
                                       N  =  [ 2p x (100-p)   x    f(, )]/102 
                                            = (2 x 94 x 6x 10.5)/ 102   
                                            = 118 individuals in the smallest arm 
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Considering that other trials have reported loss to follow-up and withdrawal rates of 10% 
in 28days follow-up periods, we Assumed a 20% loss to follow up and withdrawal  for a 
42 days follow-up which allows a size of 142.  Randomization in the ratio of 2:2:1 for 
artesunate-amodiaquine: dihydroartemisinin-piperaquine and artemether-lumefantrine 
will be done.  A minimum of 142 cases for the artemether-lumefantrine arm, and 284 
cases for each of the two tested arm (Arsucam® and Duo-cotecxin®) will be required, to 
make a total of 710 cases for both study sites. For purposes of block randomisation, a 
sample size of 720 was preferred.  
  3.1.2 Study procedure and sampling 
 Screening and Recruitment 
In conformity with routine malaria diagnosis at the study sites, the same flow of patients 
was maintained.  On the morning of the study day (day 0), the investigator's medical 
team approached potential candidate children with acute uncomplicated falciparum 
malaria.  Randomisation of patients to trial allocation and pre-treatment investigations 
(clinical and laboratory assessments) was be started when subject inclusion/exclusion 
criteria have been met and written informed assents are obtained.   Informed assents 
for study participation was obtained from their parents/guardians (signatures or thumb 
impressions).  The parents/guardians was informed verbally as well as in writing about 
the nature of the study, the anticipated risks and benefits, the discomfort to which the 
subjects was exposed, as well as the right to interrupt the participation at any time on 
their own free-will. The contents of the subject information/informed assent sheet will be 
explained (Appendix II). The information procedure was also attended by an 
independent witness to assure that the contents of the written subject 
information/informed assent sheet have been explained to the subjects. A literate 
witness will also sign the informed assent form in addition to a  non-literate participant.  
All subjects screened for the study were registered in Identification of Screened and 
Enrolled Participants Log to indicate their demographics.  
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 Inclusion and Exclusion criteria 
 The criteria for inclusion of participants for the study were as follows: 
 Children of either gender, aged between 6 months (> 5kg) and 10 years. 
 Children Suffering from acute uncomplicated P. falciparum malaria confirmed by 
microscopy using Giemsa-stained thick film with an asexual parasite density of 
1,000 to 100,000 parasites/μl. 
 Children presenting with fever (axillary temperature ≥ 37.5oC) or having a history of 
fever in the preceding 24 hours.  
 Ability to ingest tablets orally (either suspended in water or uncrushed with food). 
 Willingness to participate in the study with written assent from parent/guardian. 
Parental authorization was obtained for children less than 8 years old and 
documented assent of parents/guardians for children 8-10 years. 
 Willingness and ability to attend the clinic on stipulated regular follow-up visits. 
A child was excluded from being enrolled to the study if any of the following “danger 
signs of severe malaria”:  were observed: 
 
 Not able to drink or breast feed 
 Persistent vomiting (>2 episodes within previous 24 hours) 
 Convulsions  (>1 episode within previous 24 hours) 
 Lethargic/unconscious 
 Signs/symptoms indicating severe/complicated malaria according to WHO 
criteria (WHO definition). 
 Concomitant illnesses, underlying chronic hepatic or renal disease, abnormal 
cardiac rhythm, hypoglycaemia, jaundice, respiratory distress, 
 Serious gastrointestinal disease, severe malnutrition (W/H < 70%) or severe 
anaemia (haemoglobin < 5 g/dl). 
 Known hypersensitivity to the study drugs. 
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- Randomisation 
Block-randomisation stratified per centre was used to allocate the patients to the three 
trial arms. The block size was 30 and blinded only to the treating physicians but not the 
pharmacy attendant who administers the drug. The actual randomization was computer 
generated by the statistician attached to the project. The numbers so generated were 
placed each in an opaque envelope. Each envelope contained a paper with the 
assigned random trial arm (Study Arm-A, B, or C) but numbered serially. 
 Randomisation was done only after informed assent for study participation and patient 
inclusion and exclusion criteria have been met. Each study participant was assigned the 
next lowest randomisation number (patient‟s study ID number). This ID number was the 
subject‟s unique identifier and was used to identify the subject on the CRF and in 
labelling all study-related laboratory samples. 
 Parasitological Assessments 
During follow up, finger-prick blood samples was collected from patients for malaria 
examination every 8 hours in the first three days and thereafter followed up weekly on 
days 7, 14, 21, 28, 35, 42, and at any time (unscheduled visit) when 
parasitaemia/clinical signs and symptoms of malaria reappears. Parasitaemia was 
considered cleared if 2 consecutive negative smears occured during the first 3 days.   
Re-infection was distinguished from recrudescence through the analysis of the msp1, 
msp2 and glurp genes. 
 Clinical Assessments 
Clinical assessments was performed in all visits on patients in all trial arms and at any 
time when parasitaemia/clinical signs and symptoms of malaria reappeared.  During 
hospital visits, vital signs including body temperature was recorded. 
 Molecular Markers of Recrudescence/Re-infection  
Finger-prick blood was collected in filter papers during follow up on days 7, 14, 21, 28, 
35, 42 and at any time when parasitaemia/clinical signs and symptoms of malaria 
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reappeared. The analysis of molecular markers was done only when blood smears for 
malaria were found positive. 
 Evaluation of Trial Response 
Patient‟s trial outcome was classified according to the WHO guidelines (WHO 2003) 
with application as follows: 
(1) Early Treatment Failure (ETF)  
Development of danger signs or severe malaria on day 1, 2 or 3 in the presence of 
parasitaemia; or Parasitaemia on day 3 with axillary temperature > 37.5 o C; or 
Parasitaemia on day 3, with 25% of count on day 0; or adverse events > grade 3 
requiring change in treatment on days 0-2. 
(2)      Late Clinical Failure (LCF) 
Development of dangers signs or severe malaria after day 3 in the presence of 
parasitaemia without previously meeting any of the criteria of ETF; or Presence of 
parasitaemia and axillary temperature >37.5 o C (or history of fever in past 24 hours), 
on any day from days 4 onwards, without previously meeting any of the criteria of ETF. 
(3)   Late Parasitological Failure (LPF) 
Presence of parasitaemia on any day from days 7 onwards and axillary temperature 
<37.5 o C, without previously meeting any of the criteria of early treatment or late 
clinical failure. 
 (4) Adequate Clinical and Parasitological Response (ACPR) 
Absence of parasitaemia on day 42 irrespective of temperature without previously 
meeting any of the criteria of early treatment failure or late clinical failure or late 
parasitological failure 
 3.1.3 Ethical Considerations 
Ethical approval was obtained for the study protocol, any amendments, the informed 
assent or any other aspect of study required by Ethics Committee both in Cameroon 
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and the Ethics Review Committee of the World Health Organisation (WHO-ERC) before 
initiation of the trial. 
All artemisinin derivatives including artemether, artesunate and artemisinin have been 
proven safe with minimal adverse reactions.  As a consequence we did not for see any 
problems as result of the children taking the drugs under study. We however were 
aware from prior trials with these drugs that artesunate amodiaquine may cause itches 
or rashes while artemether lumefantrine and dihydroartemisinin may cause some 
headaches. To minimise these risks, the partipants were monitored and treated 
immediately when any of the adverse events were observed. 
Patients included in the study received potential benefit directly from treatment with 
either one of the three trial regimens (artemether-lumefantrine, artesunate-amodiaquine 
and dihydroartemisinin-piperaquine). These ACTs have proven effective for treatment of 
acute uncomplicated falciparum malaria in different areas of the world with cure rate of 
more than 90% and fever and parasite cleared within 48 hours after treatment.  Indirect 
benefit to the participants was that they had an opportunity to have a detailed medical 
and physical examination, laboratory tests, follows up visits at home and treatment of 
common illness of infants and children in the home of the participants. Finally, it was our 
hope that knowledge gained from the study will provide useful information on policy-
decision on effective treatment regimens in Cameroon. 
A data safety and monitoring board (DSMB) was put in place to monitor the data from 
the study for any safety concerns and to take appropriate action 
3.2 Molecular analysis 
3.2.1. Extraction of malaria parasite and human DNA 
The following genes were assessed: 
 Plasmodium falciparum Pfmsp2 gene to distinguish between recrudescence and 
reinfection 
 Plasmodium falciparum pfmdrI N86Y gene conferring drug resistance,  
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 NAT 2 human gene for therapeutic response 
DNA (both for human genomic DNA and parasite) was extracted from blood spots on 
filter papers (Whatmann 3MM) by the chelex boiling method described by Plowe et al., 
(1995).  The necessary materials were sterilized by autoclaving, and the working areas 
including other equipment were disinfected with 10% bleach and 70% alcohol.  
The blood spots were carefully excised from the filter papers, transferred into eppendorf 
tubes containing 1ml of 0.5% saponin in 1X sterile PBS for cell lysis. The tubes were 
inverted several times and kept at 40C overnight. The next day, the brown solution was 
discarded and the filter papers washed with 1ml of 1X PBS and kept at 40C for 15-
30minutes. The supernatant was then discarded and the filter paper in each tube was 
transferred into their corresponding 1.5ml eppendorf tubes, each containing 50µl of 20% 
chelex-100 plus 150µl of DNAase free water, previously placed in the heat-block set at 
1000C a few minutes before, and not forgetting to clean the pair of forceps between 
samples.  
After allowing samples in the heating block for 10 minutes the samples are agitated for 
30 seconds and placed once again in the heating block for a further 10minutes. This is 
repeated twice for each tube. The tubes were centrifuged at 13200rpm for 3minutes and 
the supernatant collected in fresh microfuge tubes. Centrifugation was repeated for 3 
minutes and the supernatant collected into fresh tubes, taking care not to pick up any 
chelex crystal. The solution (DNA) was then stored at -200C until use. 
      
3.2.2 PCR genotyping of pfmsp2 gene (Adjusted cure rate to differentiate between 
recrudescence and reinfection) 
The genetic fingerprinting technique nested Polymerase Chain Reaction, based on the 
polymorphic antigen loci pfmsp2, pfmsp1 and Glurp gene (Plasmodium falciparum 
merozoite surface protein 2) was used in this study to determine wheter P. falciparum 
parasites recurring in a patient‟s peripheral blood after antimalarial treatment (Failure, 
Day X) are genetically identical to, or different from the parasites present prior to 
treatment (Baseline, Day zero). Numbers of studies have found that among the above 
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cited markers pfmsp2 is so far the highly polymorphic with allelic variants (bands) 
ranging from 4, 5 to 6 in endemic settings. Here the pfmsp2 gene marker was used. If 
identical to pre-treatment parasites, the recurrent infection is considered to be a 
recrudescence; if different it is considered to be newly emerging from the liver 
(hypnozoites, dormant form).  
In this assay the product of the first amplification was used as the template for the 
second amplification in which a different set of primers was used (nested PCR).   
The final volume of each PCR mixture in each tube was 25µl. The reaction mixture of 
each tube consisted of 18.25µl of molecular biology water, 2.5µl of 10X thermopol 
buffer, 0.5µl of 10nM dNTPs (New England Biolabs), primers (S3 and S4) (Table 3.1), 
obtained from MR4, USA and 0.25µl of Taq polymerase, (New England Biolabs USA). 
Each tube for the outer PCR contained 22µl of PCR reagents which was made up to 
25µl by adding 3µl of the corresponding DNA. The tubes were then placed in the T3 
thermal cycler (Biometra, U.K) with the following conditions; pre-denaturation 940C for 
3minutes followed by 40 cycles of denaturation at 940C for 30seconds, annealing at 
420C for 60seconds, elongation 650C for 2minutes and final extension at 720C for 
3minutes. 
 For the nested PCR, each tube contained 24µl of PCR which was made up to 25µl by 
adding 1µl of amplicon from the outer PCR. Each experiment included a negative 
control and a positive control containing P. falciparum genomic DNA. The tubes were 
then introduced in the thermal cycler machine (T3 Biometra) and subjected to the 
following conditions; pre-denaturation at 940C for 3 minutes, followed by 30 cycles of 
denaturation at 940C for 30seconds, annealing at 500C for 60seconds, elongation at 
720C for 2 minutes and final extension at 720C for 3minutes. 
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Table  3.1: Primer sequences for msp 2 gene 
Gene PCR Primers Sequence  (5‟→3‟) 
Msp-2 
 
Outer  S2  GAG GGA TGT TGC TGC TCC ACA G 
 S3  GAA GGT AAT TAA AAC ATT GTC 
 Nested  S1  GAG TAT AAG GAG AAG TAT G 
 S4  CTA GAA CCA TGC ATA TGT CC 
Legend: PCR = Polymerase chain reaction, msp-2 = merozoite surface protein 
 
3.2.3 Amplification of pfmdr gene 
The final volume of each PCR mixture in each tube was 25µl. The reaction mixture of 
each tube consisted of 18.25µl of molecular biology water, 2.5µl of 10X  thermopol 
buffer, 0.5µl of 10nM dNTPs (New England Biolabs), primers (MDR1 and MDR2) (Table 
3.2), obtained from MR4, USA, and 0.25µl of Taq polymerase (New England Biolabs 
USA). Each tube for the outer PCR contained 22µl of PCR reagents which was made 
up to 25µl by adding 3µl of the corresponding DNA. The tubes were then placed in the 
T3 thermal cycler (Biometra, U.K) with the following conditions; pre-denaturation  940C 
for 3minutes followed by 40 cycles of denaturation at 940C for 30seconds, annealing at 
560C for 30s, elongation at 600C for 1 minute and final extension at 600C for 3minutes. 
 For the second amplification (inner PCR), the reaction was performed in a 25µl reaction 
mixture each containing 20.25 µl of nuclease free water, 2.5 µl of 10X Thermopol buffer, 
0.5µl of 10mM dNTPs, 0.25µl of each primer (MDR3 and MDR4) 2.5µM, 0.25 µl of Taq 
DNA polymerase (New England Biolabs), and 1µl of amplicon from the outer PCR 
amplification. All were put in the different microfuge tubes which had been previously 
labelled, as well as the positive control tube. The mixtures were subjected to the 
following amplification conditions; pre-denaturation at 940C/3min, followed by 30 cycles 
of denaturation at 940C/30s, annealing at 480C/30s, elongation at 640C/60s and final 
extension at 640C/3min.  
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Table  3.2: Primer sequences for the amplification of pfmdr 1 gene 
Gene PCR Primers Sequence  (5‟→3‟) Amplicon 
Size 
Pfmdr 
I 
 
Outer MDR1 GCGCGCGTTGAACAAAAAGAGTACCGCTG  
Ca. 300 bp 
MDR2 GGGCCCTCGTACCAATTCCTGAACTCAC 
 Nested MDR3 TTTACCGTTTAAATGTTTACCTGC 
MDR4 CCATCTTGATAAAAAACACTTCTT 
Legend: PCR = Polymerase chain reaction, Pfmdr = Plasmodium falciparum multidrug 
resistance 
 
The amplicons obtained here were later subjected to restriction digest as described 
below. 
3.2.4 Restriction Fragment Length Polymorphism (RFLP) analysis for Pfmdr1 
mutation (N86Y) conferring resistance  
Some clones (genetic diversity) are of clinical interest as they may harbor genes 
conferring drug resistance and thus be selected by treatment, causing therapeutic 
failure. In this study mutation analysis (SNP) in the resistance gene pfmdr1 was done to 
differentiate between pure mutant types (86Y), pure wild types (N86) and mixed 
infections (N86Y). The presence of polymorphism in a DNA fragment can result in the 
loss or the gain of a restriction site in that fragment (Syaffruddin et al., 2005). Thus, a 
gain of restriction site for the enzyme Afl III indicate the presence of polymorphism. 
- Afl III digestion 
Afl III digests specifically DNA sequences carrying the mutant allele 86Y(Tyr). This 
enzyme is extracted from the E. coli bacterial strain that carries the Afl III d‟Anabaena 
flos-aquae and recognizes the following DNA sequence: 
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Digestion was done into a total reaction mixture of 20 µl in a sterile 1.5ml eppendorf 
tube containing: 1.5µl of Afl III restriction enzyme (5Units/ µl) (New England Biolabs), 
3µl of 10X buffer 3 (NEB 3) and 0.2µl of 100X bovine serum albumin (BSA). The volume 
was made up to 12µl by adding 7.3µl of nuclease free water. A total of 8µl of amplicon 
from nested PCR was added into each tube and the mixtures incubated in a 
thermocycler at 37oC for 20 hours.    
 
3.2.5 PCR genotyping of the NAT-2 gene 
Genetic differences in the capability of individuals to metabolize drugs can explain the 
inter-individuals variability observed within a population; resulting in different and 
diverse therapeutic response. Genetic polymorphism (SNP) has been found in the NAT 
2 gene where it influences the biotransformation rate of individuals, which in this case 
can be categorized as slow acetylators, fast acetylators and intermediate acetylators. 
NAT 2 gene is an enzyme involved in the metabolic pathway of phase II 
biotransformation/elimination of xenobiotic. The identification of SNPs herein may be 
relevant in establishing the genetic profile for toxicity with a usual dose of a given drug, 
establishing the genetic profile for favorable response to a given drugs, just to cite a 
few. 
A single run conventional PCR was used for the amplification of NAT-2 gene based on 
the methodology proposed by Chen et al., 2007 with slight modifications.  The reaction 
mixture of each tube consisted of 36.5µl of molecular biology water, 5µl of 10X  
thermopol buffer, 1.0 µl of 10mM dNTPs (New England Biolabs), 0.5 µl of each primers 
(NAT-1F and NAT-1R) (Table 3.3), obtained from MR4, USA, and 0.5µl of Hot start Taq 
polymerase (5Units/ µl) (New England Biolabs USA). Each tube of PCR contained 44µl 
of PCR reagents which was made up to 50µl by adding 6µl of the corresponding DNA. 
The tubes were then placed in the T3 thermal cycler (Biometra, U.K) with the following 
conditions; pre-denaturation 950C for 15 minutes followed by 40 cycles of denaturation 
at 950C for 50 seconds, annealing at 550C for 50s, elongation at 720C for 50 seconds 
and final extension at 720C for 3minutes. 
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Table  3.3: Primer sequences for the amplification of NAT-2 gene 
Gene Primers Sequence  (5‟→3‟) Amplicon Size 
NAT-2 
 
NAT-1F CCAATAAAAGTAGAAGCGA  
535 basepair 
 
NAT-1R CTCTTCCAGGACCTCCA 
 
3.2.6 Restriction Fragment Length Polymorphism (RFLP) analysis for the NAT-2 
gene polymorphism 
As earlier stated the presence of polymorphism in a DNA sequence can result in a gain 
or loss of restriction site. In this study we analyzed 4 SNPs namely: 
 
- NAT 24 wild type (fast acetylator) 
- NAT 25 mutant type (slow acetylator) 
- NAT 26 mutant type (slow acetylator) 
- NAT 27 mutant type (slow acetylator) 
 
The polymorphisms were analyzed by using the following restriction endonucleases: 
- Kpn I: the absence of a restriction site is characteristic of the presence of the NAT 
25 mutation as compare to the wild type, which possesses a restriction site for the 
same restriction enzyme 
- Taq I: characterizes the absence of one restriction site on the mutant type NAT 26 
as compare to the wild type NAT 24, which possesses two restriction sites for the 
same restriction enzyme  
- Bam HI: the absence of a restriction site is characteristic of the presence of the NAT 
27 mutation as compare to the wild type, which possesses a restriction site for the 
same restriction enzyme 
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- Intermediate acetylator: Is characterized by the presence of a wild type and the 
presence of a mutant type; NAT 24/ NAT 25, NAT 24/ NAT 26, NAT 24/ NAT 
27 
If there is complete digestion of an allele by the three restrictions enzymes Kpn I, Taq I, 
and Bam HI then it permits to rule out the absence of all the mutant types and 
consequently this is considered to be NAT 24 allele. The expected possible 
combinations are described latter in results (Table 4.4). 
 
- RFLP analysis by Bam HI enzyme 
Bam HI enzyme is extracted from the E. coli bacterial strain that carries the Bam HI 
gene from Bacillus amyloliquefaciens H and recognizes the following DNA sequence: 
 
 
 
Digestion was done into a total reaction mixture of 20 µl in a sterile 1.5ml eppendorf 
tube containing: 7.3µl of nuclease free water, 3µl of 10X buffer 3 (NEB 3), 0.2µl of 100X 
bovine serum albumin (BSA) and 1.5µl of BamHI restriction enzyme (20 Units/ µl) (New 
England Biolabs), and The volume was made up to 20µl by adding 8µl of amplicon from 
PCR. The mixture was incubated in a thermocycler at 37oC for 16 hours.   
 
- RFLP analysis by Kpn I enzyme 
Kpn I enzyme is extracted from the E. coli bacterial strain that carries the Kpn I gene 
from Klebsiella pneumoniae and recognizes the following DNA sequence: 
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Digestion was done into a total reaction mixture of 20 µl in a sterile 1.5ml eppendorf 
tube containing: 7.3µl of nuclease free water, 3µl of 10X buffer 1 (NEB 1), 0.2µl of 100X 
bovine serum albumin (BSA) and 1.5µl of Kpn I restriction enzyme (10 Units/ µl) (New 
England Biolabs), and The volume was made up to 20µl by adding 8µl of amplicon from 
PCR. The mixture was incubated in a thermocycler at 37oC for 16 hours.    
 
- RFLP analysis by TaqαI enzyme 
Taq alpha I enzyme is extracted from an E. coli bacterial strain that carries a Taq alpha I 
overproducing plasmid and recognizes the following DNA sequence: 
 
 
Digestion was done into a total reaction mixture of 20 µl in a sterile 1.5ml eppendorf 
tube containing: 7.3µl of nuclease free water, 3µl of 10X buffer 4 (NEB 4), 0.2µl of 100X 
bovine serum albumin (BSA) and 1.5µl of Taq alpha I restriction enzyme (20 Units/ µl) 
(New England Biolabs), and The volume was made up to 20µl by adding 8µl of 
amplicon from PCR. The mixture was incubated in a thermocycler at 65oC for 16 hours.    
 
3.2.7 Agarose gel electrophoresis of PCR products and digests 
The final PCR products and digests were revealed using agarose gel electrophoresis. A 
1.5 to 2% gel was prepared by weighing 0.75-1.0g of agarose (Seakem Nusieve) into 
50ml of 1X TBE buffer in a 250ml duran bottle. The mixture was placed on the bunsen 
burner for about 15minutes, after which it is allowed to cool down to about 600C. 2.5µl of 
EtBr was then added to the gel, swirled gently and carefully poured into the gel casting 
tray, and then allowed for about 45mins to solidify. A total 10µl of the final product of 
PCR was carefully mixed with 2.5µl DNA loading buffer and loaded into the wells that 
had been immersed into the electrophoresis tank containing TBE buffer. The molecular 
weight marker (10µl) was also loaded into one of the wells. The set up was connected 
to current after closing the lid. The DNA migrated with respect to charge to give different 
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band sizes. The distance migrated by the DNA was visually monitored by tracking dyes 
(bromophenol blue). The band sizes were visualized with the aid of a U.V trans-
illuminator and photographed using a digital camera. The distance migrated by each 
gene was measured against that of molecular weight marker. The molecular weight of 
each gene was determined graphically from the curve of log10 of molecular weight 
marker against the distance migrated by interpolation. 
3.3 Data analysis and Modeling 
3.3.1 Data management  
As a quality assurance measure, data was double entered using Microsoft Office 
Access 2007. Statistical software SPSS version 17 (Somers, NY) was used for data 
management and processing. Data was analysed using the software R version 2.11.1. 
The main analysis for efficacy parameters was done using both the intention-to-treat 
(ITT) and per-protocol(PP). For the modeling stage the per protocol dataset was used. 
3.3.2 Descriptive  analysis of Primary objectives 
PCR-adjusted parasitological cure rates on Day 42 were compared using χ2 test as well 
as the odds ratios for likelihood of cure with 95% CIs. Both the intention to treat and per 
protocol dataset were used. 
3.3.3 Descriptive  analysis of secondary objectives 
First the PCR Adjusted results was shown indicating samples that we considered 
recrudescence or re-infection. Also the molecular results indicating the distribution of 
the study population according to whether they are slow or fast metabolisers were 
assessed. 
PCR-adjusted therapy outcome per treatment arm were assessed for day 14 and 28 
and compared across the different treatment arms by χ2 test. Kaplan Meier curves for 
FCTs and PCTs were plotted to determine any difference by site and treatment. 
Similarly, safety variables were analysed using ITT. Comparison of categorical variables 
between the two trial groups vs control arm was analysed using χ2 test. Comparison of 
continuous variables such as changes in laboratory parameters following treatment) 
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between groups was assessed by the Wilcoxon signed-rank test for data conforming to 
non-normal distribution or by the paired t-test for data conforming to normal distribution. 
3.3.4 Non-inferiority of ASAQ and DHP to AL 
We showed non-inferiority of ASAQ and DHAP compared to AL by constructing a 2 
sided 100(1-2α)% confidence interval (CI) for the difference of cure rates of ASAQ and 
DHAP when compared to AL. We construct the the 95% CI of the difference in cure 
rates of patients in the AL arm compared to DHP and ASAQ by using the formula: 
         
Where p1,p2 are respectively the cure rates ofdrug1 and drug 2 and q1 and q2 are 1-
cure rates of drug1 and 2 respectively. n1 and n2 are the number of patients under 
drug 1 and 2 respectively. We then compare the upper bound of these 95% CI with the 
non-inferiority margin (10%). If the upper bound is less that 10%, we conclude non-
inferiority. 
3.3.5. Explorative multivariate modelling  
-Variable selection 
The covariates used for the two models are the site(Garoua or Mutengene), the 
drug(AL, DHP or ASAQ), the residence type(urban or rural), the ecological type(sahel or 
forest or savannah), the sex(male or female),age group(<=60years,>60years), weight 
and temperature. Given that some suspected liver function test and haematological 
parameters were assessed only on the day 0,7and 42,  we consider only the day 0 
values with the assumption that their influence on response is constant all through the 
visit days. To this end, we include, alanine amino transferase level(abnormal rage, 
normal range), creatinine levels(abnomal, normal) and neutrophil levels(abnormal, 
normal), haemoglobin level(low, normal), acetelator status(slow metaboliser , fast 
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metaboliser). All normal or abnormal ranges are according to the Cameroonian 
population as stipulated in the protocol of the study.(see annex5) 
-Model selection strategy 
Selection of Model would be by the Akaike Information Criterion(AIC) using the step 
function in R 2.11.1 in preference to stepwise model selection which usually have an 
inherent biases in parameter estimation, inconsistencies among model selection 
algorithms, and an inappropriate focus or reliance on a single best model[136]. The 
model with the least AIC value would be selected. 
Modeling Treatment outcome(Adequate Clinical and parasitological 
response) 
Given that treatment outcome is measured only at one time point (day 42) according to 
the per protocol data set, we fit a logistic regression to find out the influence of the 
covariates on outcome of treatment. 
A simple logistic regression with one  predictor can be represented by: 
 
where π is the probability that the outcome of interest(in this case cure) occurs and β is 
the coefficient of the predictor(covariate) X and α is the y intercept . In this 
representation x can be either continuous or categorical. but the response which is 
whether the patient is cured (yes/no) can only be categorical. The value of β, 
determines the direction of the relationship between X and the natural log odds of Y. 
Odds ratios can easily be calculated from this model by taking the exponential of the 
coefficient (β )of a binary variable. 
We start up with a full model comprising of all the covariates under investigation and by 
use of  a step function in R 2.11.1, we access several models while comparing their 
Akaike Information criterion (AIC) value. We select the model with the least AIC value 
as our best model.. The only assumption for a logistic regression is the binomial 
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distribution assumption for the conditional mean  for the outcome(cure or not cured). 
This assumption is however tenable as the binomial distribution assumption is robust as 
long as the sample is independent. This is the case in our study and so we do not check 
this assumption. Parameter estimates are considered significant at 0.05 level. 
 
- Modeling delayance to  parasite clearance 
In this model, Response variable is the time to parasite clearance. We start by first 
plotting Kaplan Meier survival curves to understand the evolution of the different factors 
that are suspected of playing in role in the time to complete clearance of parasite.  This 
would help feed the modeling stage. 
Time in this study is the visit days( 0, 1, 2, 3, 7, 14, 21, 28, 35 and 42). Parasites can 
get cleared at a particular time and only get recorded on a visit day. Therefore only an 
interval of time when parasites are cleared is recorded. The methods of survival 
analysis using time as a continuous variables are not very appropriate in this setting. . 
We rather fit a discrete time survival model with day of visit as the discrete time. 
One important question in a time to event setting is the distribution of the hazard with 
time(hazard function). These are simply the probabilities of having the event at time t 
given no event before t. Given that the hazard function are probabilities, cox(1972)  
reparameterised these probabilities to have a logistic dependence on predictors and 
timeThe discrete hazard model is given by:  
 
 
where [D1ij  , D2ij , . . . ,DJij  ] are sequence of dummy variables with values [d1ij  , d2ij , . . . 
,dJij  ] indexing time periods. J refers to the last period observed for anyone in the 
sample. [α1 , α2 ,..., αJ] represent the baseline level of hazard in each time period and the 
slopes[β1 , β2 ,... , βp]  describe the effects of predictors on the baseline hazard function 
particularly on a logistic scale.Taking log transformation for the equation(2) above  , we 
obtain(Singerwillet et al,1993) 
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Hazard funtion transformed this way gives us the conditional log odds that an event will 
occour in each time point(visit day) given that the individual did not get the even in the 
previous time point(visit) as a linear function of αj specific to time j, and the values of the 
predictors at time j multiplied by the appropriate slopes(βp). 
This model is fitted using glm function in R.2.11.1 software with logit function as link 
function. 
To fit this model using logistic regression, we first convert the data to a person- time 
data set such that each subject(record) has one record corresponding to the discrete 
observed time and therefore the number of records for each subject corresponds to the 
number of discrete observed times till the event is observed as shown in figure 3.1 
As in the case of modeling response to therapy, we start off with a full model with all the 
covariates selected and then by using the step function , we access several models and 
select the model with the least AIC values. 
Figure 3.1: Example Data transformed to person-data time for fitting discrete time 
survival model using logistic regression 
Subjnumber Sitecode Drug Age_group Temp Par cleared Visit day 
3 1 ASAQ 0 38 52,400 0 0 
3 1 ASAQ 0 36 240 0 1 
3 1 ASAQ 0 36 0 1 2 
4 1 AL 0 38 14,320 0 0 
4 1 AL 0 37 160 0 1 
4 1 AL 0 37 0 1 2 
"cleared" is the event status variable and "visit day" is the observed discrete time  
we assess hazard conditional probabilities by plotting predicted probabilities per  time 
point and per predictor. 
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Based on the fitted conditional  hazard probabilities the survival probability at time j can 
be obtained by equation(4).  
 
 
Where hk is the conditional probabilities at time j. The estimated values of S j where 
j=1,2,..K is used to plot the survival function. 
To fit the Discrete time model, we assume that the linear-logistic model is a valid 
representation of reality(linearity),that all heterogeneity is across individuals is 
accounted for by the variation of the values of the covariates  and that the logit -hazard 
profiles correspond to all possible values of every predictor are distinguished only by 
their relative elevation(proportionality). We proof linearity assumption by fitting a 
generalised additive model and smoothing out the continuous variables degrees of 
freedom of these continuous variable close to 1 indicate linearity. Also show assumption 
of no unobserved heterogeneity we fit a mixed model with each subject as a random 
effect and a very small variation accounted by the random effect will show that all the 
covariates in our model cover almost all the variation in the data. The proportional odds 
sequence of discrete time models indicates that the the proportional assumption is valid 
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Chapter 4: Results 
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4.1 Patient Flow and baseline characteristics  
4.1.1 Patient flow 
In total, 2500 children were screened from which 720 were randomised and enrolled 
into the three treatment arms (Figure 4.1). Of these, 697(23 never completed treatment) 
treatment outcomes were available in the intention-to-treat (ITT) while 623 outcomes 
were available in the per protocol analysis.  
 
 
Figure 4.1:Study profile showing the number of patients recruited into each arm 
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4.1.2 Patient baseline characteristics  
There was no significant difference in baseline characteristics (Table 4.1) across the 3 
treatment arms.  
 
Table 4.1: Baseline characteristics of randomised Study Participants 
 
4.2 Descriptive  analysis of Primary objectives 
 4.2.1 Efficacy 
The PCR- unadjusted cure rates for the intention to treat analysis were 80.4% (111/138) 
for AL, 81.4% (227/279) for ASAQ and 80.4% (225/280) for DHP (p=0.9). Per protocol 
analysis of unadjusted PCR cure rates on day 42 were 91% (112/123) for AL, 89.4% 
(228/255) for ASAQ and 89.4% (219/245) for DHP (p=0.86) . The intention to treat 
analysis of PCR adjusted cure rates on day 42 were 92% (127/138) for AL, 91% 
(260/279) for ASAQ and 89% (251/280) for DHP  (p=0.31).  PCR adjusted per protocol 
analysis cure rates on day 42 were 96.7% (119/123) for AL, 98.1% (250/255) for ASAQ 
and 96.3% (236/245) for DHP (p=0.75).  
  
Characteristics     ASAQ AL DHP 
P-
value 
 Age*(months)±SD 55.35±34.5 57.97±33.8 54.88±32.9 0.67 
 Weight*(kg)±SD 16.9 ±7.3 17.8±7.7 16.9±6.8 0.41 
 Auxillary temperature*(°C)±SD 38±1.1 38±1.1 37.8±1.1 0.5 
 Haemoglobin*(g/dl)±SD 10.4±2.14 9.9±2.1 9.9±2.1 0.44 
 
Parasite density**(/µl) 
13555(1000-
100000) 
14808(1000-
100000) 
13690(1000-
100000) 0.71 
 
Creatine mg/l 0.65±0.46 0.73±1 0.68±0.72 0.48 
 ALAT IU/l 
 
30±52 25±23 26±28 0.81 
 Absolute neutrophil count /µl 47±18 48±19 47±18 0.76 
 sex(male:female) (145:131) (63:75) (142:137) 0.5 
 *  mean ±SD(standard Deviation) 
** Geometric mean and range 
ASAQ = artesunate amodiaquine; DHP = dihydroartemisinin piperaquine;  AL = artemether lumefantrine 
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The PCR adjusted per protocol odds of being cured being in the AL compared with 
ASAQ arm is 0.987[95%CI(0.951,1.024)] and the odds of being cured being in the AL 
compared with DHP arm is 1.004[95%CI(0.964,1.046)] 
4.3 Descriptive analysis of secondary objectives 
4.3.1  Molecular analysis results 
-PCR-Adjusted cure rate: distinction between recrudescence and re-infection 
Out of the 79 (22 from Mutengene, and 57 from Garoua) patients that failed therapy as 
confirmed by Microscopy on the field, an analysis of pfmsp2 gene was done to 
distinguish between recrudescence and re-infection. Sixteen recrudescence cases were 
identified with 10 from Mutengene and 6 from Garoua. A typical agarose gel 
electrophoresis permitted to differentiate between identical genotypes with the same 
base pair size at baseline D0 and failure day DX (recrudescence) and different allelic 
variants with different base pair sizes on D0 and DX (new infection) (Figure 4.2).  
 
 
 
 
 
 
 
Legend: samples 1D0, 1DX   are new infections and samples 2D0, 2DX are 
recrudescence.   
 
 
Figure 4.2:Agarose (2%) gel electrophoresis of nested PCR products of the pfmsp2 gene 
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-RFLP analysis of pfmdr 1 N86Y polymorphism 
One of the parameters suspected of causing therapeutic failure is the presence of 
polymorphism in the pfmdr1 N86Y gene of Plasmodium falciparum. Only the 16 patients 
that presented recrudescence (true failures to treatment) were analyzed for this 
polymorphism. The PCR-Restriction Fragment Length Polymorphism (RFLP) analysis of 
the 16 recrudescence samples permitted to differentiating between pure mutant types 
(86Y), pure wild types (N86) and mixed infections (N86Y) (Figure 4.3). There were 4 
samples with pure mutant types (86Y), 1 for mixed (N86Y), 11 wild type (N86). The 
effect of Gene Polymorphism of the parasite seems not to be the main driving force to 
drug resistance in the study population. This variable is left out in further modelling 
 
 
 
 
 
 
 
 
Legend: samples 2, 3 are mixed infections, (Asn)N86/86Y(Tyr); samples 5,6,7 are wild 
types strains infections( N86); sample 8 is a pure mutant type (86Y) and sample 1 is the 
positive control for wild type (Undigested). Asn= Asparagin; Tyr = Tyrosine; pfmdr 1 = 
Plasmodium falciparum multidrug resistance; MK= 100 base pair marker.  
-Slow versus fast metabolisers ( PCR-RFLP analysis of NAT-2 gene) 
After a successful PCR amplification yielding a 535 basepair, samples were subjected 
to the action of the following enzymes: BamHI for NAT 27 mutant type, Kpn I for NAT 
25 mutant type and Taq alpha I for NAT 26 mutant type. The following profile was 
obtained (Figure 4.4). 
Figure 4.3:Agarose (2%) gel electrophoresis of PCR digests of Pfmdr 1 gene. 
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Legend: After the action of BamHI, KpnI and TaqI : 535bp and 428bp for 1B and 3B 
(NAT2*7) ; 535bp and 483bp for 1K and 3K (NAT2*5) ; 330bp, 205bp and 170bp for 1T 
and 3T (NAT2*6) ;  (4) Undigested control for wild type; (2) 100 basepair (bp) molecular 
weight marker. The numbers represent the samples and the letters BKT stand 
respectively for BamHI, KpnI and Taq alpha 1.  
The band pattern obtained after digestion with these three enzymes was combined for 
interpretation of phenotypes and genotypes (part of annex 1 ). 
- Distribution of fast and slow metabolisers per site and treatment arm  
In the two population groups, Mutengene presented slow and fast metaboliser 
phenotypes higher than in Garoua whereas the intermediate phenotype was more 
represented in Garoua(figure 4.5a). Merging the intermediate phenotype to slow, the 
distribution of metaboliser status were similar across the treatment regimens(figure 
4.5b).   
 
 
 
 
 
 
Figure 4.4:Agarose (2%) gel electrophoresis of NAT-2 gene digests. 
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legend; DHP = Dihydroartemisinin piperaquine, AL = Arthemeter lumefantrine, AS-AQ = 
artesunate amodiaquine. Fast metaboliser=both fast and intermediate phenotype ; slow 
metaboliser=slow phenotype 
 
4.3.2 Efficacy and therapy outcome on day 14 and 28 
Comparing therapy outcomes for the different treatment arms show no significant 
difference for both day 14 (p=0.51) and 28 (p=0.78) respectively. No early treatment 
failure was observed amongst patients in the artemether lumefantrine and artesunate 
amodiaqine arm (Table 4.3) on day 14 and 28.  All failures in DHP and AL arms had 
occurred by D14 and no more before D28. On the contrary, 7 more failures occurred 
between D14 and 18 for ASAQ.  
Table 4.2:: PCR adjusted Efficacy outcomes(per protocol analysis) for Day 14 and 
Day 28 
    Day 14       Day 28     
outcome ASAQ DHP AL P-value ASAQ DHP AL P-value 
ACPR 250 236 119 
0.51 
243 236 119 
0.78 
ETF 0 2 0 0 2 0 
LCF 2 4 1 7 4 1 
LPF 2 3 3 4 3 3 
 
ASAQ = artesunate amodiaquine;   DHP = dihydroartemisinin piperaquine; AL = 
artemether  lumefantrine 
ACPR = adequate clinical and parasitological response, ETF = early treatment failure; LCF 
= late clinical failure, LPF = Late parasitological failure. 
 
Figure  4.5:Distribution of fast and slow metabolisers by site and treatment arm 
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4.3.3 Safety of the  three treatment arms 
There was a significant change in the Haemoglobin(g/dl) level in patients in the DHP 
(p=0.001)and AL(P=0.001)(Table 4.3) between Day 0 (D0) and Day 7 (D7), while no 
significant difference was observed in  children who were administered ASAQ. 
Table 4.3:Difference in patients mean haemoglobin levels((g/dl) on day 0 and day 
7 by treatment arm 
Treatment D0 D7 D7-D0 *P-value       
ASAQ 10.4 9.9 0.49 0.35 
   DHP  9.9 9.5 0.50 0.001 
   AL 9.9 9.3 0.55 0.001    
 
Out of a total of 249 adverse events recorded across the different follow-up days, one of 
them was a serious adverse event in which the child was suffering from severe fatigue. 
This child was in the artemether lumefantrine arm. Most of the adverse events were 
cough, vomiting and lack of Appetite. The distribution of adverse events according to 
their intensity irrespective of the possible cause show that most of them were mild and 
less severe (Table 4.4) 
Table 4.4: Number of adverse events irrespective of causality with respect to 
treatment and intensity 
 
        
 
Intensity 
   Treatment 1 2 3 4 Total     
ASAQ 56 36 6 1 99 
  DHP 71 34 4 1 110 
  AL 24 15 0 1 40 
  Total 151 85 10 3 249     
Intensity(1=mild,2=moderate,3=severe,4=very severe) 
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Amongst those adverse events whose cause was suspected to be the drug, there was 
no statistical significant difference (p value=0.83) when comparing the three treatments 
with respect to the intensity of adverse event (Table 4.5).  
Table 4.5:Number of adverse events with drug as the probable cause with respect 
to treatment and intensity 
 
                                Intensity 
   Treatment 1 2 3 4 Total   
ASAQ 37 25 3 1 66 
  DHP 46 23 2 1 72 
  AL 15 8 0 1 24 
  Total 98 56 5 3 162 
  Intensity(1=mild, 2=moderate, 3=severe, 4=very severe) 
There was no difference between liver function test-creatinine, aminotransferase 
(ALAT), aspartate aminotransferase (ASAT) across the different treatment  arms 
4.4  Non Inferiority testing 
The 95% confidence interval for the difference in cure rates of ASAQ with AL(PAL-
PASAQ)  is 0.014 ±1.96(0.000435)=[-0.015, -0.013] and the 95% confidence interval for 
the difference in cure rates of DHAP with AL(PAL-PDHP) is 0.004±1.96(0.000405)= 
[0.003, 0.005]. All the upper bounds of these intervals are less than the inferiority 
margin of 0.1 and therefore we have proven the non-inferiority of DHAP and ASAQ 
when compared to AL.  
4.5: Parasite clearance time and Fever Clearance time 
4.5.1: Proportion of patients with parasitaemia with respect to time 
Proportion of patients with parasitaemia with respect to time were similar across the 
three study arms (Figure 4.6).  
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There was however a little site effect on parasite clearance. About 18% of children  in 
Garoua clear their parasites by day one compared to 8% in Mutengene.(figure 4.7) 
Comparing the proportion of patients with parasite clearance with respect to time across 
the different treatment arms and site did not show any appreciable difference. 
 
 
 
 
 
 
Figure 4.6:Parasite clearance time per treatment arm 
Figure 4.7:Parasite clearance time per site and treatment arm 
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4.5.2 Proportion of patients with fever with respect to time 
The Kaplan Meier curve for fever clearance shows a pretty similar pattern across the 
three treatment arms. However a pair wise comparison using the log rank test showed a 
significant difference between the ASAQ and DHP(p value=0.04). 
 
 
 
 
 
 
 
 
 
 
Patients in ASAQ-arm cleared fever better than those in DHP arm However, no 
significant difference (p=0.21) was found between the treatment groups with respect to 
fever clearance time (FCT) at day 3  
4.6  Modeling treatment outcome and delayance t o parasite clearance 
4.6.1 Exploratory Data analysis  
Exploring the relationship between the continuous variables that would be used to fit the 
multivariate model on therapy outcome, indicate that only weight and age of patients 
have linear relationship (Figure 4.9). 
Figure 4.8:proportion of patients with fever with respect  days after treatment. 
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A look at the distribution of the outcome (adequate clinical response) with the different 
continuous variables. The box plots below all show that only the neutrophil levels on day 
zero and age of patients show a difference in their distribution when comparing with the 
outcome status. Patients who have a positive outcome (cured) coded as "1" are older 
and have  more of their neutrophil levels above the median neutrophil level  than that 
their counterparts who are not cured coded as "0"(Figure 4.10). 
 
 
 
 
 
 
 
Figure 4.9:Correlation between continuous variables 
Figure 4.10:Relationship between the outcome (ACPR) and continuous variables 
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4.6.2 Multiple logistic regression 
The full model with all covariates as described in methods section(not shown here) was 
fitted and non of the suspected predictors were significant at 0.05 level of significance. 
However the full model showed age group >5years to have an effect at 0.1 significant 
level. 
Using the step function in R 2.11.1 as way of looking for the best fitting model, we 
compared the AIC values and taking the model with least values. The final model was 
fitted and is shown in Table 4.7 
 
Table 4.6:Final model of Treatment outcome using logistic regression: 
    Final model     
Predictors   β(S.E) 
  Age_group>5yrs 
 
0.39(0.50) 
  Site(Mutengene) 
 
0.99(0.60). 
  ASAQ 
 
0.24(0.74) 
  DHP 
 
0.37(0.68) 
           
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
The final model showed no significant covariate at 0.05 level of significance However, at 
0.1 level of significance, the site effect is significant. The odds of getting cured given 
that you are in Mutengene site is 2.69(е(.99)) 
4.5.1 Exploratory Data analysis using Kaplan Meier survival estimates 
The Kaplan-Meier Survival estimates in the following results, indicates the probability of 
patients still persisting with parasitaemia at the different times (days after treatment). 
Figure 4.12 shows a distinct difference in the probability of survival on day across the   
three treatment arms with dihydroartemisinin piperaquine having the least probability of 
survival. However on day two, all of the treatments have a probability of lower than 0.1 
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with patients in dihydroartemisin arm still having the least probability of survival (having 
parasites still persisting) when compared to the other drugs in the study. 
 
 
 
 
 
 
 
 
 
On day one, patients who have genes NAT2 genes that make them fast metabolisers 
have less probability of surviving (parasites still persisting) than their slow metabolisers 
counter parts. This trend does not continue to day two where patients have the same 
probability of survival irrespective of their metaboliser status (Figure 4.13). 
 
 
 
 
 
 
 
Figure 4.11:Kaplan-Meier survival estimates for persistence parasitaemia 
Figure 4.12:Kaplan-Meier survival estimates for fast and slow metaboliser 
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When age of patients is categorised into patients below 5 years of age and those above 
5 years of age, there was no comparative difference between these groups with respect 
to their survival rates on any of the follow-up (Figure 4.14). 
 
 
 
 
 
 
 
Grouping the patients under study into whether they had the normal range of 
haemoglobin (haemoglobin levels<10g/l) levels or not seem to be time dependent.  One 
day after treatment, the kaplan meier survival shows that those with low haemoglobin 
levels have a lower probability of persisting with parasite than those on those with 
normal haemoglobin ranges (Figure 4.15) 
 
 
 
 
 
 
 
 
Figure 4.13:Kaplan-Meier survival analysis for children according to age groups. 
Figure 4.14:Kaplan-Meier survival analysis estimate with respect to haemoglobin level 
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When the patients are categorized into normal and abnormal with respect to the normal 
range in Cameroon (42-72)% neutrophil levels, the Kaplan-Meier survival curves show 
that those with abnormal neutrophil levels have a higher probability of persistent 
parasites in the first two days after treatment (Figure 4.16). 
 
 
 
 
 
 
Kaplan Meier survival estimates of the trend in parasite clearance with respect to site 
show that patients in Garoua have a lower probability of having their parasites persist 
on day one than their Mutengene site counterpart. The trend continues to day two but is 
not as appreciable as in day one (Figure 4.17 ). 
 
 
 
 
 
 
 
 
Figure 4.15:Kaplan-Meier survival estimates for children with respect to neutrophil level 
Figure 4.16:Kaplan-Meier survival estimates for children with respect to site 
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4.5.2 Fitting the discrete time survival model 
The results of the discrete time fitted model in  (Table 4.8), show the main effects of 
time(model 1) and the full model incorporating time and all the variables chosen for 
modeling(model2) and the final model which is gotten through assessing different 
models and judging best fit by the Akaike Information criteria.  
Model 1 shows that day 1, 2, 3, 7 and 14 are the important days which influence 
parasite clearance. All analysis that follow would look at trends in parasite clearance 
using these days as time point. 
In the  final model, the age group, site, ALAT level on first hospital visit, creatinine level 
on first hospital visit, and the interaction between age group and site are important in 
determining time to parasite clearance(significance level of 0.05). However, at 
significance level of 0.1, the haemoglobin level is significant. 
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Table 4.7:Discrete time survival model parameter estimates with standard errors for 
Model 1,2 and 3 
        
 
Model1 Model 2 Final Model 
Predictors β(S.E) β(S.E) β(S.E) 
day1 4.48(0.42)*** 4.63(0.43)*** 4.72(0.42)*** 
day2 6.41(0.44)*** 7.14(0.48)*** 7.20(0.46)*** 
day3 6.01(0.61)*** 6.75(0.65)*** 6.74(0.64)*** 
day7 5.06(0.61)*** 5.04(.63)*** 5.09(0.62)*** 
day14 6.66(1.14)*** 6.60(1.16)*** 6.64(1.14)*** 
day21 -8.99(535.41) -9.77(533.41) -9.52(535.41) 
Sex(male) 
 
-0.10(0.15) 
 Age_group>5yrs 
 
-0.76(0.40). -0.68(0.22)** 
Site(Mutengene) 
 
4.05(1.29)** -2.15(0.25)*** 
ASAQ 
 
-0.14(0.36) 
 DHP 
 
-0.17(0.36) 
 fast metaboliser 
 
0.03(0.16) 
 normal neutrophils level day0 
 
-0.13(0.16) 
 Normal ALAT level day 0 
 
0.46(0.22)* 0.45(0.22)* 
Ecotype(Forest) 
 
1.49(1.23) 
 Ecotype(Sahel) 
 
-1.26(1.70) 
 Urbanicity(urban) 
 
-0.03(0.26) 
 Weight 
 
0.01(0.02) 
 Temp 
 
-0.09(0.11) 
 Hb level>10g/dl 
 
0.26(0.16) 0.29(0.16). 
Normal Creatinine level at day0 
 
-0.64(0.21)** -0.64(0.20)** 
Age_group>5yrs*ASAQ 
 
0.12(0.41) 
 Age_group>5yrs*DHP 
 
-0.01(0.41) 
 Site(Mutengene)*ASAQ 
 
0.36(0.41) 
 Site(Mutengene)*DHP 
 
0.69(0.42). 
 Age_group>5yrs*Site(Mutengene)   1.00(0.31)** 1.08(0.31)*** 
AIC 1206.7 1145.6 1125.2 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
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A table of odds ratios of the final model show that those with normal ALAT ,Hb levels on 
first day of visit have a higher chance of clearing their parasites earlier than their 
counter parts with abnormal levels  
 
Table 4.8:Hazard Odd ratios and 95%  CI for variables in the final model 
Odd ratios and 95% CI for significant variables of final model 
Predictors Odd ratio estimate 95% CI 
Age_group>5yrs 0.51 (0.33,0.78) 
Site(Mutengene) 0.12 (0.07,0.18) 
Normal ALAT level day 0 1.56 (1.02,2.40) 
Hb level>10g/dl 1.34 (0.98,1.82)* 
Normal Creatinine level at day0 0.52 (0.35,0.78) 
Age_group>5yrs*Site(Mutengene) 2.94 (1.62,5.38) 
*not significant 
   
 
  However, having normal Creatinine levels is associated with delay in parasite clearance 
than those with abnormal creatinine levels(usually lower levels than minimum normal 
level).Parasite clearance is delayed in mutengene (OR=0.12) in general influence is 
modified whether the child is older than 5years or not. 
 
The time effect on the hazard function(figure 4.18a) indicates that on day 2, there is a 
high chance of children clearing their parasites if they had not already done so on day 1. 
By day 3, most children have cleared their parasite(see survival function-figure 4.18b) 
 Figure 4.17:Hazard and survival probability profiles of the time effect on parasite clearance 
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Mutengene lags behind Garoua in parasite clearance especially from day 1 and 2. Older 
children in Mutengene has a better parasite clearance prognosis than the younger 
ones(figure 4.19a). In Garoua(see figure 4.19b) it is rather younger children who clear 
their parasites earlier(day 1 especially) than the older children. 
 
 
 
 
 
 
The alanine aminotransferase(ALAT) level influences time to parasites clearance. 
Those with normal normal ALAT levels on first day of visit remain consistent with a 
higher chance of  clearing their parasites by each visit day on condition that they did not  
clear on a previous visit day. For day 2 , for example, the probability of clearing 
parasites normal ALAT level is 83% while for abnormal ALAT level is 76% given that the 
parasites were not cleared on day 0. 
 
 
Figure 4.18:Hazard and survival probabilities by site and age group 
Figure 4.19:Hazard and survival probabilities by ALAT level 
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Patient creatinine levels also influence how fast malaria parasites get cleared. Those 
with a Cameroonian specific normal creatinine level (see annex on normal ranges) have 
lower chance of clearing their parasites by each visit day given they had not cleared in 
the previous day than those that have abnormal creatinine levels.  
 
 
 
 
 
 
 
 
Even though haemoglobin levels is not  a very important(significant only at 0.1 level of 
significance) covariate that influences time to parasite clearance, we show that there is 
a trend in which those with low haemoglobin levels lag behind those with a normal 
haemoglobin level in clearing parasites(figure 4.22) 
 
 
 
 
Figure 4.20:Hazard and survival probabilities by creatinine levels 
Figure 4.21:Hazard and survival probabilities by haemoglobin levels 
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4.5.3 Discrete time survival Model Diagnostics 
We fitted a generalised additive model using the variables of the full model while 
smoothing weight and temperature which are the only continuous covariates. Weight 
had degree of freedom of 1.001 while temperature had a degree of 3.077. Even though 
the smoother for temperature has more than 1 degree of freedom, it is not significant(p 
value=0.16). Therefore the linearity assumption of the predictors is tenable. 
Fitting a mixed model to the final selected predictors and with subjects or individual 
patients as random effects, we get the variance captured by random effects to be 
0.00000078 with standard deviation of 0.00028 which is very negligible. Therefore the 
assumption of no unobserved heterogeneity in the model is valid. Therefore there is 
evidence that our assumptions for this discrete time survival model hold. 
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Chapter 5: Discussion 
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Efficacy, safety and Non inferiority of Drugs 
Artemisinin-based combination therapies (ACTs) continue to gain ground as the most 
efficacious treatment for uncomplicated Plasmodium falciparum malaria. Many studies 
are looking at the comparative efficacy of the different ACTs in settings where the 
treatment is most likely to be used[137]. These studies seek to better inform malaria 
experts and health policy makers on the preferred ACTs or alternatives [137] for the 
different malaria endemic countries[100-102] . This study has compared the efficacy of 
ASAQ, DHP and AL in the same population during the same period. 
 
Results presented herein show high cure rates for the different treatment arms for 14, 
28 and 42 follow-up days of follow up. These results are consistent with results from 
studies in other malaria endemic countries in Sub-saharan Africa [101] [102]. The high 
cure rate is consistent in the two sites with different ecologies and climatic conditions. 
The high cure rates of these anti-malaria drugs and the effective use of insecticide 
treated bed nets could significantly reduce morbidity and mortality in Cameroonian 
population (NMCP Cameroon Report 2012) 
 
Although the difference is not significant,  studies have shown that the dietary cow milk 
which is one of the main nutrition source for the   Fulani community  is speculated to 
have an immuno protective activity with the potential to act also against drug resistant 
forms of the malaria parasite [20], [140]. This study shows similar ACTs cure rates in  
Mutengene and Garoua and therefore supports the nationwide implementation of ACTs 
irrespective of geography and ethnicity and brings an added advantage towards malaria 
elimination. 
The authorities in the Ministry of Health in Cameroon are fighting the illicit sale of 
medication by road vendors and unauthorized agents. There is still a wide circulation of 
competing drugs to those enforced by the government for treating malaria. The situation 
is worsened with stock outs of antimalarials at the different recognized distribution 
centers [141].  Patients are obliged to search for alternatives without proper information 
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on the source of anti-malarial, its efficacy and tolerability. The non-inferiority of the study 
drugs compared to widely used artemether lumefantrine will enable care givers to make 
informed prescription decisions. The use of alternative available efficacious and safe 
drugs is helpful in delaying the antimalarial drug resistance that is beginning to emerge 
[24]  
With the reports of emergence of drug resistance to the very efficacious artemisinin 
combination therapies, there is need to monitor the efficacy and safety of these drugs 
closely. One way to monitor anti-malaria drug resistance in the absence of validated 
molecular markers and appropriate in vitro models is by analyzing parasite clearance  
times [142]. Parasite clearance time curves represented by the proportion of patients 
that clear parasites with respect to the time from onset of treatment did not show any 
appreciable delay across the three study drugs. There is still the need for planned 
monitoring of the in vivo parasite clearance times for the different ACTs currently used 
in Cameroon. 
The proportion of patients with a temperature below 370C after the 3rd day of first 
treatment and who remain so for the next 48 hours show similar patterns across the 
different study drugs. However pair wise comparison showed a difference between 
Patients in the ASAQ treatment compared to the  DHP treatment group.. This difference 
however only suggests that patients under ASAQ treatment as compared to DHPand 
AL  get relieved of the symptom much faster. This does not have any implications on 
the efficacy of the drugs. 
The change in liver function tests: creatinine, alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT) did not show any significant difference between day 
0 and day 7 values across the three drug regimens under study. However, there is a 
significant difference in the day 0 and day7 haemoglobin levels of patients in the AL and 
DHP. This therefore suggests that patients in the ASAQ treatment group are more likely 
to achieve convalescence before their counterparts in the AL and DHP treatment group. 
Though there is need for further research, this result also suggests that Iron tablets 
alongside AL, DHP might be considered in management of malaria patients. 
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Treatment Outcome model 
Patients‟ ability to fight diseases plays a major role in any therapy outcome. In some 
studies, characteristics like age, sex play great role. Given that the outcome is 
measured only on day 42 for per protocol analysis, we go for a logistic regression. 
Malaria has be shown to associated with anemia (low haemoglobin levels) especially 
during pregnancy [143]. However some artemisinin combination therapies like ASAQ 
and AL increase haemoglobin levels from day 0 to day 28 at different rates [144]. Even 
though haemoglobin levels are low in patients with malaria, the sickle cell haemoglobin 
plays a protective role against malaria [145]. High haemoglobin level is protective 
against high parasitaemia which also reduces the risk of severe malaria [145]. 
 
In our Logistic model, low haemoglobin levels have not been  associated with an 
unfavorable treatment outcome to the drugs.  
 
singlet oxygen have been shown to be the neutrophil product responsible in supressing 
the growth of parasistes. [146]. Neutrophils , which play a great role in adverting 
infections in humans according to our model do not(not significant) influence treatment 
outcome. All the drugs under study have not shown any association with 
neutropenia(low neutrophil levels). Therefore, there is a synergy between high 
Neutrophils level and treatment in the treatment outcome. Children under the age of 10 
who are the cohort under this study are exposed to many infections due to the fact that 
their immunity is still for the most part innate and therefore, a combined effort by health 
practitioners (in Cameroon especially ) needs to be directed to fight other infections 
common to this age group to save these efficacious drugs . 
 
Alanine aminotransferase(ALAT) which is one of the regular liver function test in any 
drug tolerability study was not selected in our final model as a predictor for therapy 
outcome. Aline aminotransferase is indicative of liver injury. Dihydroartemisinin which is 
one of the drugs in this study has been shown to have been associated with elevated 
levels of alanine amintransferase [41] . The liver which is a vital organ of the human 
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system is responsible for metabolism and is very crucial in drug intake to the target 
cells. A healthy liver will therefore favour a positive outcome of any treatment including 
all anti malarials. Alanine amino transferase not influencing therapy outcome according 
to our model might mean  that our study population tolerate the drugs  so well . 
The drugs which patients are prescribed also play a great role in therapy outcome. In 
our study, the treatment arm to which the patient is, has little or no predictibility to 
whether the patients gets cured or not. This result is inconsistent with studies that show 
that first line treatments to malaria must not be global but be on a region basis [147]. In 
Cameroon, there is a high drug pressure with many drug vendors that are not licensed 
[141] there is is need for health care givers  to be aware that AL,DHP and ASAQ could 
be used as first line drugs and does not jeopardise cure. Drug regulation authorities 
would save the very efficacious drugs by  stringently regulating the type of anti-malarials 
sold with preference with these three(AL,ASAQ,DHP) 
 
Parasite clearance time 
In this study we sought to model parasite clearance time in two ecologically regions 
(Mutengene and Ngaoundéré) in children age six months to 10 years following 
treatment with Arthemeter-Lumefantrine (AL), artesunate-amodiaquine (ASAQ) and 
Dihydroartemisinin piperaquine (DHP). With the delay in the parasite clearance time 
that might have contributed to artesunate-mefloquine resistance at the Thai-Cambodia 
border ways , circumventing or delaying the onset and spread of resistance have been 
proposed among which is the implementation of multiple first line therapies  [39] [24].  
 There are many contributing and interrelated factors that are associated to  delay of 
parasite clearance . Integrating these factors in models gives better estimation of each 
contributing factor to the delayance. Others have proposed and used models which 
express best the parasite clearance rate and using clearance time as a continuous 
variable(white et al). In our study, we fitted a discrete time survival model  and the 
interaction of age group and site was significant. However, the relationship between age 
group and site is not consistent across the two sites. In mutengene,older children(>5yrs) 
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have a higher probability of clearing the parasite than their younger(<=5yrs). In Garoua, 
the relation is reversed to that in mutengene with younger children clearing parasites 
faster. This is  inconsistent with  studies that have suggested age to be an inadequate 
surrogate marker [148] for immunity especially in low malaria transmission areas. This 
model has shown that patients in Mutengene lag behind those in Garoua especially at 
one and two days after treatment in clearing their parasites. This might be due to that 
fact that patients in  Mutengene which is a high malaria transmission rain forest area 
have persistent parasitaemia.  
Patients who are  fast metabolisers are more prone to have parasite persisting on day 
one probably owing to the availability of plasma drug [148]. This was not evaluated in 
our study. However when comparing time to parasite clearance with respect to patients 
metaboliser status, it was not significant. 
Patients with normal ALAT on their first visit to the hospital would clear their parasites 
faster than those with abnormal levels. This trend is also true for normal haemoglobin 
levels even though it is only significant at 0.1 significant level. Abnormal creatinine 
levels(most have lower creatinine levels than normal) have shown to favour faster 
parasite clearance. Abnormal ALAT levels and elevated creatinine levels are indicative 
of an infection in the case of ALAT and start of failure of kidneys in case of creatinine. 
This therefore means a better prognosis in terms of parasite clearance would be 
achieved if health givers can treat all co infections as well. Abnormal haemoglobin 
levels would also compromise the time to parasite clearance. 
 
 
 
 
 
 
 
 
 
97 
 
Chapter 6: Conclusion and Recommendation 
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6.1 Conclusion 
Even though at the start of this study, the government policy for first line treatment of 
plasmodium falciparium malaria was artemether lumefantrine, this research has shown 
that artesunate amodiaquine and dihydroartemisinin piperaquine are also highly 
efficacious with cure rates of 98.1% and 96.3% respectively. Better still, this study has 
shown that these two drugs(artesunate amodiaquine and dihydroartemisin piperaquine) 
are at least not worse off(with a 10% margin of inferiority) than artemeter lumefantrine in 
the treatment of Plasmodium falciparum malaria in the cameroonian children. 
The three drugs in this study are comparatively safe. However those who were treated 
with dihydroartemisin piperaquine and artemeter lumefantrine show a reduction in 
haemoglobin levels compared to the levels of the first day of treatment. There was no 
significant difference when comparing the frequency of the adverse events(mostly 
vomiting, cough and lack of appetite) that were suspected to be caused by drug, across 
the different treatments. 
The characteristics or variables considered in our outcome model do not influence cure 
rates. However, those in Mutengene at 0.1 significant level are at least two 
times(OR=2.7) as likely to be cured than those in Garoua.  
 
There is a delayance in Parasite clearance in Mutengene compared to Garoua 
especially on day 1 and 2. This delayance is further modified in each site by age group.  
Abnormal creatinine, alanine aminotransferase , and haemoglobin levels before taking 
AL,ASAQ and DHP for the treatment of malaria compromise the time to parasite 
clearance in the blood stream. 
6.2 Recommendation 
The national malaria control program of Cameroon which is the Main malaria control 
policy maker should expand their first line treatment of plasmodium malaria to include 
artemether lumefantrine, dihydroartemisinin piperaquine and artesunate amodiaquine 
which  have been shown to be very efficacious against malaria. 
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Due to the drop in haemoglobin levels after treatment with these drugs, policy should 
include association of iron replenishing drugs and vitamin B12 with these anti-malarials. 
Given that creatinine and alanine aminotransferase levels play arole according to this 
study in the time to parasite clearance,control efforts to curb other infections that are 
common with children under the age of 10 years is crucial. This will boost efficacy and 
therefore prolong the time to appearance of drug resistance to these very efficacious 
anti malarials 
A more in-depth study on why patients in forest region(mutengene) lag behind those in 
the sahel savannah region(Garoua) of Cameroon is crucial. This would help understand 
how other factors that were not considered in this study could usher in drug resistance.  
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Annex 1: Human NAT-2 haplotypes 
NAT2 Allele  
(Haplotype)
a  
Nucleotide Change(s) 
and rs Identifiersb  
Amino Acid 
Change(s)b  
Phenotypec  
NAT2*4  Reference  Reference  Rapid  
 
NAT2*5A  
341T>C(rs1801280) 
481C>T (rs1799929)  
I114T  
L161L 
(synonymous)  
 
Slow  
 
NAT2*5B  
341T>C(rs1801280) 
481C>T(rs1799929) 
803A>G (rs1208)  
I114T L161L 
(synonymous)  
K268R  
 
Slow  
 
NAT2*5C  
341T>C(rs1801280) 
803A>G (rs1208)  
I114T K268R   
Slow  
NAT2*6A  282C>T(rs1041983) 
590G>A (rs1799930)  
Y94Y 
(synonymous)  
R197Q  
Slow  
NAT2*6B  590G>A (rs1799930)  R197Q  Slow  
NAT2*6C  282C>T(rs1041983) 
590G>A(rs1799930) 
803A>G (rs1208)  
Y94Y 
(synonymous)  
R197Q K268R  
Slow  
NAT2*6D  111T>C  
282C>T (rs1041983) 
590G>A (rs1799930)  
F37F 
(synonymous)  
Y94Y 
(synonymous)  
R197Q  
Slow  
NAT2*7A  
 
857G>A (rs1799931)  G286E  Slow Substrate 
dependent?  
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NAT2*7B  282C>T(rs1041983) 
857G>A (rs1799931)  
Y94Y 
(synonymous)  
G286E  
Slow  
Substrate 
dependent?  
NAT2*10  499G>A  E167K  Slow  
Substrate 
dependent?  
NAT2*11A  481C>T (rs1799929)  L161L 
(synonymous)  
Rapid  
NAT2*11B  481C>T (rs1799929) 
859Del  
L161L 
(synonymous)  
S287 Frame shift  
Unknown  
NAT2*12A  803A>G (rs1208)  K268R  Rapid  
NAT2*12B  282C>T (rs1041983) 
803A>G (rs1208)  
Y94Y 
(synonymous)  
K268R  
Rapid  
NAT2*12C  481C>T (rs1799929) 
803A>G (rs1208)  
L161L 
(synonymous)  
K268R  
Rapid  
NAT2*12D  364G>A (rs4986996) 
803A>G (rs1208)  
D122N K268R  Slow  
NAT2*13A  
 
282C>T (rs1041983)  Y94Y 
(synonymous)  
Rapid  
NAT2*13B  282C>T (rs1041983)  
578C>T  
Y94Y 
(synonymous)  
T193M  
                          
NAT2*14A  191G>A (rs1801279)  R64Q  Slow  
NAT2*14B  191G>A (rs1801279) 
282C>T (rs1041983)  
R64Q  
Y94Y 
Slow  
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(synonymous)  
NAT2*14C  191G>A (rs1801279) 
341T>C (rs1801280) 
481C>T (rs1799929) 
803A>G          (rs1208)  
R64Q I114T L161L 
(synonymous)  
K268R  
Slow  
NAT2*17  434A>C  Q145P  Slow  
NAT2*18  845A>C  K282T  Rapid  
NAT2*19  190C>T (rs1805158)  R64W  Slow  
NAT2*20  600A>G(rs72466461)  synonymous   
NAT2*21  458C>T(rs72466460)  T153I   
 
Table 4.2: Possible genotypes and phenotypes combination after RFLP analysis 
 
 
Bands for 
BamHI (pb) 
Bands for KpnI 
(pb) 
Bands for TaqI 
(pb) 
Genotypes Phenotypes 
428 ; 107 483 ; 52 205 ; 170 ; 160 NAT2*4/4 Fast acetylator 
428 ; 107 535 205 ; 170 ; 160 NAT2*5/5 Slow acetylator 
428 ; 107 483 ; 52 330 ; 205  NAT2*6/6 Slow acetylator 
535 483 ; 52 205 ; 170 ; 160 NAT2*7/7 Slow acetylator 
428 ; 107 535 ; 483 ; 52 330 ; 205 ; 170 ; 
160 
NAT2*5/6 Slow acetylator 
535 ; 428 ; 107 535 ; 483 ; 52 205 ; 170 ; 160 NAT2*5/7 Slow acetylator 
535 ; 428 ; 107 483 ; 52 330 ; 205 ; 170 ; 
160 
NAT2*6/7 Slow acetylator 
428 ; 107 535 ; 483 ; 52 205 ; 170 ; 160 NAT2*4/5 Intermediate 
acetylator 
535 ; 428 ; 107 483 ; 52 205 ; 170 ; 160 NAT2*4/7 Intermediate 
acetylator 
428 ; 107 483 ; 52 330 ; 205 ; 170 ; 
160 
NAT2*4/6 Intermediate 
acetylator 
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Annex 2:Informed Assent 
The Biotechnology Centre, Box 8094 Yaoundé University of Yaoundé I, Cameroon.  
 
 
 
 
 
1. Purpose  
There are many drugs that can be used to treat malaria..  These old drugs no longer 
cure well.  Many other drugs are being sold. Some others are being newly made and 
will be sold soon. Some of these new drugs are a combination of more than one anti-
malarial drug. In this study, we are trying to compare how well the new drugs such as 
artesunate-modiaquine (Co-Arsucam®), dihydroartemisinin-piperaquine (Duo-cotecxin®), 
and artemether-lumefantrine (CoArtem®) cure malarial infection in children.  
Your child is invited to participate in this study because your child is suffering from 
malarial infection. We will ask the permission of parents of 740 children aged less than 
5 years with acute malarial infection to take part in this study. 
2. Procedure 
If you agree for your child to be in the trial, you will be asked some questions about how 
you have treated your child in the past.  Your address will be asked so that we can visit 
your sick child. A study doctor or nurse will examine your child. We will prick your child‟s 
finger to take a few drops of blood to look for parasites. We will also take blood from the 
vein of your child, the tip of a teaspoon, to do some laboratory tests and to find out why 
some people respond quickly when treated and other people do not.  
Your child will be assigned into one of three groups to receive either artesunate-
amodiaquine, artemether-lumefantrine or dihydroartemisinin-piperaquine.   The 
assignment will be decided by chance. You and the study staffs will not know which 
group your child will be in. Your child will be given the drug at the hospital every day for 
3 days. 
We will ask you to return  with your child to the study clinic on days 7, 14, 21, 28, 35 and 
42 or at any other time if your child feels unwell.  If you and your child do not come to 
the clinic, we will visit you at your home. On followed-up day (including the they when 
Project Title: Research on Anti-Malaria Drug Resistance in Cameroon: Safety and 
Efficacy of Atemether-lumefantrine, dihydroartemisinin-piperaquine & 
Artesunate-Amodiaquine 
Principal Investigator:   Dr. Wilfred  F.  MBACHAM; 
Study Number ______________  
Subject’s  Name _____________________________  
Subject’s code ______________ 
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clinical sign/symptom of malaria appears), your child will be examined and assessed for 
clinical symptoms of malaria. We will prick your child‟s finger to take blood to look for 
the presence of malaria in your blood and its genetics (how the parasite is made up 
inside).  At some scheduled visits, we will also take blood from your child to do some 
tests such as blood cell count, sugar level and the levels of some substance in your 
blood other  
3. Risks and discomforts 
Most children will have no problems with the drugs given but occasionally they may 
develop mild itching, rashes or intestinal upsets, headache or blurred vision.     
4. Benefits 
The drugs may help your child. However, this cannot be guaranteed. Allowing your child 
to take part in this study will benefit the community by helping to tell the doctors which 
drugs are good and how to use the new drugs for malaria. 
5. Cost 
All malaria and additional tests, drugs and hospital fee for staying in hospital during your 
child‟s involvement in the study are for free.  
6. Payment 
We will pay for your transport to bring your child back to the clinic. 
7. Alternatives 
If you decide not to take part in the study, your child will still receive the standard care in 
this hospital. This is quinine tablets.  
8. Confidentiality 
The clinical and laboratory data recorded will be kept confidential and used for this 
research only. The results of this research may be published in scientific journals or 
presented at medical meeting, but your identity will not be disclosed. 
9. Injury and Compensation 
If your child has experienced any research-related illness or injury, you can contact 
Dr.________________ at this clinic. ….(Who)…. will pay any charges required for the 
treatment of study related illness/injury. 
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10. New information and result of the study 
It is possible that new information becomes available about the medicines used in this 
study. If this happens, the study doctor will tell you about it and also discuss with you 
whether you want your child to continue in the study. If you decide not to continue, the 
study will still arrange for your child‟s care to continue. If you decide to continue in the 
study you will be asked to sign an updated parental permission form. The investigator 
will also inform you about the progress and outcome of the research. 
11. Questions 
If you feel you have not been properly told as to the discomfort, benefits or your rights,  
please feel free to take the matter to your local head of the hospital or contact the 
following people: Prof Pius Tih, Public Health Officer,  Banso Baptist Hospital, NW 
Province Cameroon(7776-4781 or  7793-6550).   
12. Voluntary Participation 
Your child‟s participation in this study is purely voluntary and you (your child) will be 
given sufficient time to decide whether or not to take part. You (and your child) may 
refuse to participate at any time and still benefit from full treatment for malaria. There 
will be no injustice, punishment, loss of benefits to which you (or your child) are 
otherwise entitled at this hospital. 
12. Acceptance  
My questions concerning this study have been answered by ------------------------------------
--------. Or I have read the information sheet concerning this study [or have understood 
the verbal explanation] and I understand what will be required of me and what will 
happen to my child if I take part in it. I understand that at any time I may withdraw my 
child from this study without giving a reason and without affecting normal care and 
management. I agree that my child should take part in the study. 
Name of Interpreter--------------------    Date ------------ 
Child's name _____________________________ 
Parent's/guardian's signature (or thumb print):________________________ 
Date____________ 
Parent's/guardian's Printed Name:____________________________ 
Witness's Signature: _________________________ Date: ___________ 
Witness's Printed Name:_________________________  
Researcher Recognizance 
The subject has been fully informed of the 
nature and purpose of the procedures 
described above including any discomfort 
involved in its performance.  The subject 
has been asked if any questions have 
arisen regarding the procedures and 
these questions have been answered to 
the best of the investigator‟s ability. 
Signature of Investigator: 
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Annex 3: R-code for the models  
Response to therapy model(logistic model) 
library(ROCR) 
library(MASS) 
# To load the file 
# load("C:/Users/Akindeh/Desktop/dataphd") 
# Creating categories(only 3 are shown here) 
newdata$Age_group <- factor(newdata$Age_group, labels=c("<=60",">60") ) 
newdata$Sitecode <- factor(newdata$Sitecode, labels=c("Garoua","Mutengene") ) 
newdata$Sex <- factor(newdata$Sex, labels=c("female", "male")) 
#Subsetting the variables to be used for model 
actualdata <- subset(modelres, select=c( Subjnumber,result_adj,Sex,Age_group,Sitecode,Drug, 
Acetelator,                        normNeutroD0,normALATD0,Ecotype,Rtype,Weight,Temp,LowHb, 
normCreaD0))  
  # To get a dataset with complete cases                                  
obsind <- which( complete.cases(actualdata) )  actualdata_cc <- actualdata[obsind,] 
write.csv2(file="actualdata_cc.csv",x=actualdata_cc) 
#Fitting the full model 
ACPR1<-glm(result_adj~ Sex+ Age_group+Sitecode+Drug+Drug*Age_group+ Drug*Sitecode +             
Sitecode*Age_group+ Acetelator+ normNeutroD0 +normALATD0+Ecotype+Rtype+s(Weight)+ s(Temp)+  
LowHb+normCreaD0,family=binomial(link="logit"), data=actualdata_cc)  print(summary(ACPR1)) 
# use the step function in R to selected the best model 
stepAIC(ACPR1) 
# fitting the final selected model using the Akaike criterion 
ACPR2 <- glm( result_adj ~ Age_group + Sitecode + Drug + Drug*Age_group, 
family=binomial(link="logit"), data=actualdata_cc) bprint(summary(ACPR2)) 
# fitting the final model, taking out the interaction of Age_group and age because of 0 cell problems 
ACPR3 <- glm( result_adj ~ Age_group + Sitecode + Drug, family=binomial(link="logit"), 
data=actualdata_cc) 
print(summary(ACPR3)) 
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R Code for the Discrete survival Model 
library(ROCR) 
library(MASS) 
#To load the file 
load("C:/Users/Akindeh/Desktop/Defence material_PHD_International Health/Submission 
Documents_Thesis_akindeh/Thesis_version3/Logistic and Discretesurvival modelling/discrete.rda") 
#load("discrete.rda") 
newdata <- discrete 
# Creating categories(only 3 are shown here) 
newdata$Age_group <- factor(newdata$Age_group, labels=c("<=60",">60") ) 
newdata$Sitecode <- factor(newdata$Sitecode, labels=c("Garoua","Mutengene") ) 
newdata$Sex <- factor(newdata$Sex, labels=c("female", "male")) 
#giving actual visit days labels to  day variable. 
newdata$day <- factor(newdata$day,labels=c("0","1","2","3","7","14","21","28","35","42")) 
#Subsetting the variables to be used for model 
actualdata <- subset(newdata, select=c( Subjnumber,cleared,day,Sex,Age_group,Sitecode,Drug, 
Acetelator,                        normNeutroD0,normALATD0,Ecotype,Rtype,Weight,Temp,LowHb, 
normCreaD0))                                        
  # To get a dataset with complete cases 
obsind <- which( complete.cases(actualdata) )    actualdata_cc <- actualdata[obsind,] 
#write.csv2(file="actualdata_cc.csv",x=actualdata_cc)  We first start up with the hazard function 
irrespective of heterogeneity therefore we fit a model with time(day)as the only covariate 
PCL0 <-glm(cleared~ day, family=binomial(link="logit"),data=actualdata_cc) print(summary(PCL0)) 
childs1 <- data.frame(day=factor(c(1)))   predday1 <- predict( PCL0, newdata=childs1,type="response") 
childs2 <- data.frame(day=factor(c(2))) predday2 <- predict( PCL0, newdata=childs2,type="response") 
childs3 <- data.frame(day=factor(c(3))) predday3 <- predict( PCL0, newdata=childs3,type="response") 
childs7 <- data.frame(day=factor(c(7)))      predday7 <- predict( PCL0, newdata=childs7,type="response") 
childs14 <- data.frame(day=factor(c(14))) predday14 <- predict( PCL0, 
newdata=childs14,type="response") 
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  # plotting the hazard function for time effect   plotdata0<- 
rbind(predday1,predday2,predday3,predday7,predday14) 
matplot(plotdata0,xaxt='n',type="l",lwd=2,xlab="Days after treatment", ylab="Conditional Probability of 
clearence",main="Hazard conditional Probabilities irrespective of heterogeneity") 
axis(1,at=1:5,labels=c(1,2,3,7,14)) 
#plotting the survival function for time effect 
surv1 <- cumprod( (1-plotdata0[,1]) )  matplot(surv1,xaxt='n', type="l",xlab="Days after 
treatment",ylab="probability parasite persistence",main='Survival probabilities irrespective of 
heterogeneity') axis(1,at=1:5,labels=c(1,2,3,7,14))  
# We fit the full Discrete model with all possible covariates  and time            
PCL1 <-glm(cleared~ day+Sex+ Age_group+Sitecode+Drug+Drug*Age_group+ Drug*Sitecode +             
Sitecode*Age_group+ Acetelator+ normNeutroD0 +normALATD0+Ecotype+Rtype+s(Weight)+ s(Temp)+  
LowHb+normCreaD0,family=binomial(link="logit"), data=actualdata_cc)   print(summary(PCL1)) 
  # checking on well the full model(model 2) classify by using a ROC curve 
pred <- prediction(fitted(PCL1), actualdata_cc$cleared)  perf <- performance(pred, measure = "tpr", 
x.measure = "fpr") plot(perf, col=rainbow(10)) 
 # use the step function in R to selected the best model 
stepAIC(PCL1) 
  # fitting the best model(final model) selected by the step function 
PCL2 <-glm(cleared~ day+ Age_group+ Sitecode+ Sitecode*Age_group+normALATD0+LowHb 
family=binomial(link="logit"),data=actualdata_cc) print(summary(PCL2))  
# Rechecking how the fit is better using the ROC curve 
Opred <- prediction(fitted(PCL2), actualdata_cc$cleared) perf <- performance(pred, measure = "tpr", 
x.measure = "fpr") plot(perf, col=rainbow(10)) 
# getting the odds ratio from the final fitted model and the confidence intervals 
OR <- exp(coef(PCL2)[-1])  OR.ci <- exp(confint(PCL2)[-1,])  
#Investigating the interaction between site and Age group on day 1,2,3,7 and 14 
childs1 <- data.frame(day=factor(c(1,1,1,1)),Age_group=factor(c("<=60",">60","<=60",">60")), 
Sitecode=factor(c("Mutengene","Mutengene","Garoua","Garoua")), normALATD0=c(0,0,0,0), 
normCreaD0=c("abnormal","abnormal","abnormal","abnormal"),              
LowHb=factor(c("<=10","<=10","<=10","<=10")) ) predday1 <- predict( PCL2, 
newdata=childs1,type="response") 
childs2 <- data.frame(day=factor(c(2,2,2,2)),   Age_group=factor(c("<=60",">60","<=60",">60")),  
Sitecode=factor(c("Mutengene","Mutengene","Garoua","Garoua")),  
normALATD0=c(0,0,0,0),normCreaD0=c("abnormal","abnormal","abnormal","abnormal"), 
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LowHb=factor(c("<=10","<=10","<=10","<=10")) )predday2 <- predict( 
PCL2,newdata=childs2,type="response") 
childs3 <- data.frame(day=factor(c(3,3,3,3)), Age_group=factor(c("<=60",">60","<=60",">60")), 
Sitecode=factor(c("Mutengene","Mutengene","Garoua","Garoua")), normALATD0=c(0,0,0,0),  
normCreaD0=c("abnormal","abnormal","abnormal","abnormal"),                   
LowHb=factor(c("<=10","<=10","<=10","<=10")) )  predday3 <- predict( PCL2, 
newdata=childs3,type="response") 
childs4 <- data.frame(day=factor(c(7,7,7,7)), Age_group=factor(c("<=60",">60","<=60",">60")), 
Sitecode=factor(c("Mutengene","Mutengene","Garoua","Garoua")), normALATD0=c(0,0,0,0),  
normCreaD0=c("abnormal","abnormal","abnormal","abnormal"),LowHb=factor(c("<=10","<=10","<=10","<=
10")) )  predday4 <- predict( PCL2, newdata=childs4,type="response") 
childs5 <- data.frame(day=factor(c(14,14,14,14)),  Age_group=factor(c("<=60",">60","<=60",">60")), 
Sitecode=factor(c("Mutengene","Mutengene","Garoua","Garoua")), normALATD0=c(0,0,0,0),  
normCreaD0=c("abnormal","abnormal","abnormal","abnormal"),                
LowHb=factor(c("<=10","<=10","<=10","<=10")) )  predday5 <- predict( PCL2, 
newdata=childs5,type="response") 
  # plotting the hazard function for the interaction between age group and site 
plotdata1 <- rbind(predday1,predday2,predday3,predday4,predday5)  matplot(plotdata1,xaxt='n', 
type="l",lwd=3,xlab="Days after treatement", ylab="Conditional Probability of clearence",main="Hazard 
Probabilities by site and age group") leg.txt <- c( "<=5yrs, Mutenegene", " >5yrs, Mutengene", "<=5yrs, 
Garoua", ">5yrs, Garoua") legend(1.7,0.5, leg.txt, cex=0.8, col=1:4, pch=21:23, lty=1:4) 
axis(1,at=1:5,labels=c(1,2,3,7,14))   
#  Plotting of Survival function for the site and age group interaction. 
surv1 <- cumprod( (1-plotdata1[,1]) )  surv2 <- cumprod( (1-plotdata1[,2]) ) surv3 <- cumprod( (1-
plotdata1[,3]) ) 
surv4 <- cumprod( (1-plotdata1[,4]) ) matplot(cbind(surv1,surv2,surv3,surv4),xaxt='n', 
type="l",lwd=3,xlab="Days after treatement", ylab="Probability of persistence of 
clearence",main="Survivial Probabilities by site and age group") leg.txt <- c( "<=5yrs, Mutenegene", " 
>5yrs, Mutengene", "<=5yrs, Garoua", ">5yrs, Garoua") legend(2.1,0.8, leg.txt, cex=0.8, col=1:4, 
pch=21:23, lty=1:4) axis(1,at=1:5,labels=c(1,2,3,7,14))   
# Plotting conditional Probabilities of parasite clearance by ALAT levels  
childs1 <- data.frame(day=factor(c(1,1)), Age_group=factor(c("<=60","<=60")), 
Sitecode=factor(c("Mutengene","Mutengene")),normALATD0=c(0,1),                     
normCreaD0=c("abnormal","abnormal"),LowHb=factor(c("<=10","<=10")) ) predday1 <- predict( PCL2, 
newdata=childs1,type="response") 
childs2 <- data.frame(day=factor(c(2,2)), Age_group=factor(c("<=60","<=60")), 
Sitecode=factor(c("Mutengene","Mutengene")), normALATD0=c(0,1),  
normCreaD0=c("abnormal","abnormal"), LowHb=factor(c("<=10","<=10")) ) predday2 <- predict( PCL2, 
newdata=childs2,type="response") 
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childs3 <- data.frame(day=factor(c(3,3)), Age_group=factor(c("<=60","<=60")),                      
Sitecode=factor(c("Mutengene","Mutengene")), normALATD0=c(0,1),                    
normCreaD0=c("abnormal","abnormal" ),LowHb=factor(c("<=10","<=10")) ) predday3 <- predict( PCL2, 
newdata=childs3,type="response") 
childs4<- data.frame(day=factor(c(7,7)), Age_group=factor(c("<=60","<=60")), 
Sitecode=factor(c("Mutengene","Mutengene")), 
normALATD0=c(0,1),normCreaD0=c("abnormal","abnormal"), LowHb=factor(c("<=10","<=10")) ) 
predday7 <- predict( PCL2, newdata=childs4,type="response") 
childs5 <- data.frame(day=factor(c(14,14)),  Age_group=factor(c("<=60","<=60")),                    
Sitecode=factor(c("Mutengene","Mutengene")) normALATD0=c(0,1),                   
normCreaD0=c("abnormal","abnormal"), LowHb=factor(c("<=10","<=10")) ) predday14 <- predict( PCL2, 
newdata=childs5,type="response") 
#Plotting hazard function for ALAT levels 
plotdata2 <- rbind(predday1,predday2,predday3,predday7,predday14) matplot(plotdata2,xaxt="n", 
type="l",lwd=3,xlab="Days after treatement", ylab="Conditional Probability of 
clearence",main="Conditional Probabilities of parasite clearance by ALAT level ") leg.txt <- c( "Abnormal 
ALAT", " Normal ALAT")  legend(1.7,0.4, leg.txt, cex=0.8, col=1:4, pch=21:23, lty=1:2)  
axis(1,at=1:5,labels=c(1,2,3,7,14))   
#  Plotting of Survival function for ALAT level w.r.t other covariates 
surv1 <- cumprod( (1-plotdata2[,1]) ) surv2 <- cumprod( (1-plotdata2[,2]) ) 
matplot(cbind(surv1,surv2), xaxt="n",type="l",lwd=3,xlab="Days after treatement", ylab="Conditional 
Probability of clearence",main="Survival  Probabilities by ALAT level") leg.txt <- c( "Abnormal ALAT", " 
Normal ALAT")   legend(2.1,0.8, leg.txt, cex=0.8, col=1:4, pch=21:23, lty=1:4) 
axis(1,at=1:5,labels=c(1,2,3,7,14))  
# hazard and survival functions for Creatinine and haemoglobin levels follow the same coding as for 
ALAT   
# model diagnostics 
# GAM model for checking on linearity assumption. the continuous variables are smoothened  
library(mgcv) 
PCL1gam <-gam(cleared~ day+Sex+ Age_group+Sitecode+Drug+Drug*Age_group+ Drug*Sitecode +             
Sitecode*Age_group+ Acetelator+ normNeutroD0 +normALATD0+Ecotype+Rtype+s(Weight)+ s(Temp)+  
LowHb+normCreaD0,family=binomial(link="logit"), data=actualdata_cc)   print(summary(PCL1gam)) 
# Mixed model to check the "no unobserved heterogeneity" assumptionlibrary(lme4) 
PCL1glmm <-glmer(cleared~ day+ Age_group+ Sitecode+ Sitecode*Age_group+normALATD0+LowHb + 
(1|Subjnumber),family=binomial(link="logit"), data=actualdata_cc)  print(summary(PCL1glmm)) 
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Annex 4: Variables used during modeling phase 
Variable Description Coding 
Sitecode Trial site 0=Garoua; 1= Mutengene 
TreatmentD0 Treatment arm into which patient is randomised  ASAQ, DHP and AL 
Result 
Is patient attained adequate clinical and parasitologic 
response(ACPR) at day 42 0= Not ACPR; 1=ACPR 
Result14 
Is patient attained adequate clinical and parasitologic 
response(ACPR) at day 14 0= Not ACPR; 1=ACPR 
Result28 
Is patient attained adequate clinical and parasitologic 
response(ACPR) at day 28 0= Not ACPR; 1=ACPR 
Age  Age of patient in months 
 
Age_group 
Variable Age dichotomised into children under 5 years and above 5 
years 0= ≤5yrs; 1=>5yrs 
Sex Patient's sex 0=female; 1= Male 
Weight Weight of patient in kgs 
 Rtype Residence type urban=0; Rural=1 
Ecotype Ecology of patient's Savannah=0; Forest=1,Sahel=2 
HbD0 Haemoglobin level at day 0 
 NeutroD0 Neutrophil level at day 0 
 AlatD0 Alanine amino transferase level at day 0 
 CreaD0 Creatinine Level at day 0 
 
Acetelator Metaboliser status 
0=Slow metaboliser; 1= fast 
metaboliser 
normHbD0 Haemoglobin level at day 0 compared to cameroonian normal range 0=Hb<10g/dl ; 1=Hb>10g/dl 
normNeutroD0 Neutrophil level at day 0 compared to  cameroonian normal range 
0= neutrophil level<42% and 1= 
otherwise 
normALATD0 
 
 
Alanine amino transferase level at day 0 compared to  cameroonian 
normal range 
 
0= alanine transferase>61; and 1 
=other wise 
 
acpr 
Testing ACPR status 
 
0= Not ACPR; 1=ACPR 
 
 
ParD0 Parasite count at Day 0   
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